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Peripheral neuropathies are a heterogeneous group of pathologies with a high 
prevalence worldwide, which are characterized by alterations of peripheral nerves 
structure and function. Their treatment is currently a challenge for clinicians. 
Indeed, even if continuous progresses are made in the study of the basic 
mechanisms underlying these pathologies, etiology is still unknown in a significant 
number of cases. Different compounds, such as, growth factors, adhesion proteins 
neurotransmitters, enzymes, peptides and neuroactive steroids, have been proposed 
to play important roles in the patho-physiology of the peripheral nervous system. 
Therefore, most of the research is addressed to identify the molecules that might 
represent the more promising therapy for this set of pathologies. 
This thesis focuses on some aspects of the patho-physiological role of the 
GABAergic system and neuroactive steroids in the peripheral nervous system. 
Several papers in literature strongly support the hypothesis that they are both 
present and active in the peripheral nervous system, in particular in Schwann cells, 
the myelinating cells of the peripheral nervous system. These cells are indeed able 
to synthesize GABA and neuroactive steroids and express both the ionotropic 
GABA-A and the metabotropic GABA-B receptor. In order to deepen the 
knowledge on this topic, four research lines were pursued in my PhD program and 
are described in this thesis. The first line regarded the analysis of the effects of 
specific GABA-B ligands on nerve regeneration in a model of neuropathic pain 
caused by nerve ligation. These studies showed that the specific GABA-B 
antagonist CGP56433 was able to recover some morphological, functional and 
biochemical parameters in peripheral nerves. Surprisingly, some of these effects 
were potentiated by the co-treatment with GABA-B specific agonist baclofen, 
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suggesting the co-activation of possible central and peripheral mechanisms. The 
second research line regarded the analysis of different GABA-A subunits in dorsal 
root ganglia (DRG) neurons of a model of conditional knockout mice, in which the 
GABA-B1 receptor is specifically deleted in Schwann cells. The results showed a 
modulation of different GABA-A subunits, pointing to a down-regulation of 
GABA-A receptors, mainly regarding the synaptic ones. This evidence may 
contribute to understand some of the alterations that were previously observed in 
this conditional knockout mouse model. The third research line dealt with the study 
of the modulation of protein kinase C-type ε (PKCε), an important neuropathic pain 
mediator, and its possible cross-talk with the GABA-A receptor and the neuroactive 
steroid allopregnanolone. The results showed that allopregnanolone down-
modulates PKCε expression in Schwann cells, but the direct treatment on DRG 
neurons did not lead to any significant effect. However, Schwann cells conditioned 
medium was able to induce a significant up-regulation of PKCε gene expression in 
DRG neurons. Also the membrane expression of PKCε phosphorylated form 
resulted to be modulated in similar way. These findings suggest a possible 
involvement of PKCε in the GABA-A mediated control of pain transmission 
exerted by allopregnanolone, also pointing out to a Schwann cell-mediated process. 
Finally, the fourth research line regarded the identification of a novel family of 
progestogen receptors localized on the cell membrane (mPRs) and PGRMC1 in 
Schwann cells; moreover, their putative role in the modulation of Schwann cell 
physiology was also investigated. The data demonstrated the expression of these 
receptors in Schwann cell plasma membrane. The treatment with a specific mPR 
agonist proved able to induce cell migration at short time points (2-4 hours) and 
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increased the expression of myelin associated glycoprotein (MAG) at longer time 
points (24-36 hours), giving a first demonstration of a role for these receptors in 
Schwann cells. The identification of this new signaling pathway will allow a better 
understanding of progestogen actions in Schwann cells. 
In conclusion, the results presented in this thesis shed some light on some basic 
mechanism controlling the patho-physiology of the peripheral nervous system, 
whose comprehension may lead to the identification of new more specific drugs for 
peripheral neuropathies treatment.  
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5-HT3: 5-hydroxytryptamine type 3. AR: androgen receptor. BDNF: brain derived 
neurotrophic factor. Ca++: calcium ion. cAMP: cyclic adenosine mono-phosphate. 
Cl-: chloride ion. CMT: Charcot-Marie-Tooth disease. CRPS-II: complex regional 
pain syndrome type II.DAG: diacylglycerol. DHP: 3α-dihydroprogesterone. DRG: 
dorsal root ganglia. ER: estrogen receptor. GABA: γ-amino butyric acid. GABA-
T: GABA transaminase. GAD: glutamic acid decarboxylase. GAP 43: growth 
associated protein 43. GDNF: glial cell line derived neurotrophic factor. GFAP: 
glial fibrillary acidic protein. GPCR: G-protein coupled receptor. HMSN: 
hereditary motor and sensory neuropathy. HSD: hydroxysteroid dehydrogenase. 
IASP: International Association for the Study of Pain. IGF2: insulin-like growth 
factor 2. IP3: inositol trisphosphate. IPSBB: slow inhibitory post-synaptic potential. 
K+: potassium ion. MAG: myelin associated glycoprotein. MAPK: MAP kinase. 
MBP: myelin basic protein. mPR: membrane progesterone receptor. mTOR: 
mammalian target of rapamycin. Na+: sodium ion. NGF: nerve growth factor. NL2: 
neuroligin 2. NMDA: N-Methyl-d-aspartate. NRG-1: Neuregulin 1. NT3: 
neurotrophin 3. NT4/5: neurotrophin 4/5. O2: 10-ethenyl-19-norprogesterone. P0: 
myelin protein zero. P450 SCC: P450 cholesterol side-chain cleavage enzyme. 
PAQR: progestin and adipoQ receptor. PDGF-BB:  platelet derived neurotrophic 
factor BB. PGRMC1: progesterone receptor membrane component 1. PIP2: 
phosphatidylinositol. PKA: protein kinase A. PKC: protein kinase C. PKs: protein 
kinases. PLC: phospholipase C. PLP: pyridoxal phosphate. PMP22: peripheral 
myelin protein of 22 KDa. pPKCε: PKCε phosphorilated form. PR: progesterone 
receptor. PXR: pregnane X-receptor. qRT-PCR: quantitative Real Time 
polymerase chain reaction. R5020: promegestone. RPA: RNAse protection assay. 
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RT-PCR: retro transcription-PCR. Serbp1: serpine mRNA binding protein 1. 
SREBP: sterol regulatory element-binding protein. SSA: succinate semialdehyde. 
StAR: steroidogenic acute regulatory protein. THDOC: tetrahydro-
deoxycorticosterone. THP: 3α,5α-tetrahydroprogesterone. TRPV1: transient 
receptor potential cation channel subfamily V member 1. TSPO: translocator 
protein of 18 KDa. VGCC: voltage-gated calcium channels. VOCC: voltage-
operated Ca++ channels. YY1: Yin Yang.  
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PERIPHERAL NERVOUS SYSTEM 
 
GENERAL CONCEPTS 
 
The nervous system is the morpho–functional unity deputed to receive internal or 
external inputs, to elaborate these stimuli and to generate a response. It is composed 
by neuronal and glial cells, blood vessels and connective tissue. It can be 
anatomically divided into central and peripheral nervous system.  
The central nervous system can be furtherly divided into encephalon and spinal 
cord. It is responsible for different important physiological functions, such as 
intelligence, memory, learning, emotions, the analysis and coordination of sensory 
data and motor output. 
In the implementation of all these crucial functions, it cooperates with the peripheral 
nervous system. The two systems are indeed anatomically and functionally 
correlated. The function of the peripheral nervous system is to link the central 
nervous system and periphery. It collects inputs, internal and external to the body, 
directing them to the central nervous system through sensitive fibers. Once this 
information has been elaborated by the central nervous system and a response has 
been generated, it is sent towards periphery (Marieb and Hoen, 2007).  
From a physiological point of view, the peripheral nervous system can be divided 
into somatic and autonomous. The somatic peripheral nervous system is formed by 
motor neurons which originate from spinal cord gray matter and make contact with 
skeletal muscles, controlling voluntary movements. The autonomous nervous 
system, instead, controls involuntary body responses, making contact with the 
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heart, visceral smooth muscles, blood vessels and glands. It can be further divided 
into sympathetic and parasympathetic nervous system, both directly originating 
from the spinal cord. In particular, sympathetic branches originate from the turaco-
lumbar portion of the spinal cord, while the parasympathetic branches originate 
from the cervical and sacral sections. The two systems exert actions that are often 
opposite each other, acting on most organs of the body. The sympathetic 
compartment is mostly activated under stressful or dangerous conditions (the so 
called “fight or flight” response), while the parasympathetic system is prevalent in 
resting situations (Marieb and Hoen, 2007).  
Nerves, which are formed by fascicles of nervous fibers, are the anatomical 
structure responsible for signal conduction. There are sensitive, motor/effector and 
mixed nerves, the latter being the most common in the peripheral nervous system 
(Figure 1). Nerve fibers are generally formed by two different components, the axon 
(that is the cellular process originating from the neuronal soma) and the myelin 
sheath formed by Schwann cells, the glial cells of the peripheral nervous system, 
that wrap around nerves in a 1:1 ratio. These fibers are called myelinated fibers, and 
are characterized by a significantly faster conductance. Not all fibers have the 
myelin sheath. In this case, they are called unmyelinated fibers, and they are 
organized in structures known as Remak bundles, in which a single Schwann cell 
envelopes multiple axons without the myelin formation (Monk et al., 2015; Feltri 
et al., 2016).  
Macroscopically, a nerve appears like a white cordlike structure with a thickness 
between 0.2 μM and 1 cm. Peripheral nerves are formed by myelinated and 
unmyelinated fibers grouped to form fascicles, separated by connective laminae that 
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also contain arterial, venous and lymphatic vessels. Single fascicles may be formed 
only by myelinated or unmyelinated fibers, or can have both type. There are three 
different connective sheaths in a nerve. Single fibers are enveloped by a sheath 
called endoneurium, several fascicles are enveloped by the perineurium, and the 
whole nerve is ensheathed by the epineurium (Marieb and Hoen, 2007).  
The cell bodies of neurons forming motor/effector nerves are located in the ventral 
horns of the spinal cord. Sensitive nerves cell bodies, instead, are grouped in 
anatomical structures called dorsal root ganglia (DRG), located outside the spinal 
cord, paravertebral to the spinal column (Figure 1).  
 
Figure 1 – Typical structure of a mixed peripheral nerve. Sensitive and motor fibers, whose cell 
bodies are localized in respectively in DRG and the ventral horn, both contribute to form the 
peripheral nerve, which originates both sensitive and motor terminals. 
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Generally, DRG are formed by pseudo-unipolar neurons, presenting a single axon 
originating from the soma that divides in a “T” shape in a peripheral and a central 
branch. The peripheral branch represents afferent fiber, which collect information 
from the periphery, while the central branch projects to the dorsal horn of the spinal 
cord (Figure 1). Neuronal soma in DRG are surrounded by a type of glial cells 
called satellite cells. They are homologous to Schwann cells and have the function 
to give structural and biochemical support to ganglia neurons (Hanani, 2005).  
As better detailed below, Schwann cells in the peripheral nervous system play a 
pivotal role in many processes besides the formation of the myelin sheath, being 
fundamental in different patho-physiological processes. Indeed, they are important 
in the development of the peripheral nervous system (Feltri et al., 2016), they are 
involved in a complex cross-talk with neurons (Taveggia, 2016; Salzer¸ 2015; 
Faroni et al., 2014), and drive the nerve regeneration process after nerve damage 
(Faroni et al., 2015; Glenn and Talbot, 2013b).  
 
SENSORY SYSTEM AND NOCICEPTIVE FIBERS 
 
As previously mentioned, peripheral nerve sensitive fibers originate from DRG 
neurons, whose axon divide into a central and a peripheral branch. The central 
branch projects towards the spinal cord dorsal horn, while the peripheral branch 
goes towards the periphery, originating sensitive terminals that can be more or less 
specific in detecting particular stimuli, such as the nociceptive one (Basbaum et al., 
2009). 
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The definition of pain, as formulated in 1986 by the International Association for 
the Study of Pain (IASP), defines it as “an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms 
of such damage”. Based on this definition, pain presents a perceptive component, 
linked to sensory and nociceptive functions, and a subjective component, 
determined by cognitive, emotional and affective state (Merskey, 1994). 
Nociception is the process by which intense thermal, mechanical, or chemical 
stimuli are detected by a subpopulation of peripheral nerve fibers, called 
nociceptors (Basbaum and Jessell, 2000; Babaum et al., 2009). Pain can be 
differentiated into acute and chronic pain. Acute pain is of short duration and it 
disappears as the pathological or harmful phenomena that caused it improves or 
heals. Chronic pain, instead, can be perceived for long periods of time and it is often 
caused by chronical pathological processes (Basbaum et al., 2009).   
Pain propagation process begins with the activation of specific receptors known as 
nociceptors. They are free nerve endings that are the distal portion of afferent 
neurons. Sensitive nerve fibers, from which they originate, can be classified by a 
neurophysiological point of view into three types, based on structure, fiber diameter 
and conduction speed (Meyer et al., 2008). The three types of nociceptive fibers are 
C, Aδ and Aβ. C fibers are unmyelinated, their diameter spans between 0.4 and 1.2 
μm and have a conduction speed of 0.5-2.0 m/s. Aδ fibers are lightly myelinated, 
with a diameter between 2.0 and 6.0 μm and a conduction speed of 12 up to 30 m/s. 
Aβ fibers are well myelinated, have diameter greater than 10 μm and high 
conduction speed, between 30 and 100 m/s. This latter category is lowly involved 
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in normal pain stimuli conduction, but it is important segmental pain suppression 
mechanisms (Millan, 1999). 
These three types of fibers show different patterns of pain propagation, depending 
of the mechanical, thermal or chemical origin of harmful stimuli they face. Aδ fibers 
rapidly transmit unimodal information generated by high intensity stimuli. They are 
responsible for the beginning of acute pain sensation, leading to the removal or 
“flight” reflex. C fibers, instead, are polymodal and carry out information slower. 
They are responsible for second pain perception, and the prolonged potentials they 
generate can sum up leading to chronic pain. This distinction is very clear in 
particular for what regards skin, but it is not necessarily so clear in every organ 
(Meyer et al., 2008).      
Aδ fibers can be divided into two groups: type I and type II fibers. Type I fibers are 
characterized by high-threshold mechanoreceptors, responding mainly to high 
intensity mechanical stimuli, with low sensitivity for chemical and thermal stimuli. 
Type II fibers, instead, are characterized by mechanical-thermal receptors, that 
respond to high (over 45°C) and low (beneath -15°C) temperature and to intense 
mechanical stimuli (Millan, 1999; Basbaum et al., 2009).  
As already mentioned, C fibers are usually polymodal, responding to different kind 
of stimuli (Perl, 2007), such as thermal and low-threshold mechanical ones, and 
specific receptors for particular algetic compounds such as K+, acetylcholine, 
proteolytic enzymes, serotonin, substance P, prostaglandins and histamine. There 
are also high-threshold C fibers, responsible for pain response following burns. 
Lastly, there are slow-conduction C fibers insensible to mechanical stimuli that 
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activate only in case of histamine-mediated inflammatory response (Millan, 1999; 
Basbaum et al., 2009).  
In pathological conditions, two different painful non-physiological conditions can 
arise: allodynia and hyperalgesia. The first is defined as a pain response generated 
by normally non-painful stimuli, the second is an excessive response to a normally 
painful stimulus (Basbaum et al., 2009).   
 
SCHWANN CELLS AND MYELINATION 
 
Schwann cells are highly specialized cells whose main function is the formation of 
the myelin sheath in the peripheral nervous system.  
Schwann cells isolating properties are fundamental for the transmission of the 
signal in myelinated fibers. Indeed, they allow saltatory conduction, electrically 
isolating the axon, except in areas comprised between two adjacent Schwann cells, 
known as nodes of Ranvier. However, Schwann cells functions go much beyond 
that, being involved in an important cross-interaction with neuronal cells and 
having a fundamental role in axonal normal development and long-term survival 
(Taveggia, 2016). They have also an important role in regenerative processes 
following nerve lesions, being able to differentiate and stimulate nerve fibers 
regeneration (Glenn and Talbot, 2013b; Faroni et al., 2015). On the other hand, 
axons provide signals that regulate Schwann cell proliferation, survival and 
differentiation, as well as myelin formation (Bozzali and Wrabetz, 2004; Simons 
and Trajkovic, 2006; Woodhoo and Sommer, 2008; Taveggia et al., 2010). 
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Schwann cells derive from cell precursors which originate from the neural crest 
during embryogenesis (Le Douarin et al., 1991, Figure 2). A fundamental 
determinant in Schwann cell lineage determination is NRG-1, since it suppresses 
neuronal differentiation and promotes glial differentiation (Shah et al., 2004). 
Schwann cell precursors are migratory and proliferative (Monk et al., 2015), and 
rely on axonal signals for survival (Dong et al., 1995). They are characterized by 
the expression of specific differentiation markers, like the growth associated protein 
43 (GAP 43) and F-Spondin (Debby-Brafman et al., 1999; Byrstyn-Cohen et al., 
1998).  
 
Figure 2 – Steps of Schwann differentiation. Schwann cell precursors, deriving from the neural 
crest, differentiate into immature Schwann cells, that are responsible for the radial sorting process. 
Once radial sorting is complete, immature Schwann cell differentiate into the myelinating or non-
myelinating phenotype. Adapted from Monk et al., 2015. 
 
The following differentiation step leads to the formation of immature Schwann cells 
(Figure 2). Notch signaling has been reported to be a key regulator of this process, 
indeed its inactivation decreases Schwann cell precursor proliferation and their 
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transition to immature Schwann cells, while its over activation up-regulates both 
processes (Woodhoo et al., 2009). In this differentiation step, cells stop to migrate 
and become less dependent on axonal signaling, since their survival now depends 
on autocrine factors. Among them, an important role is played by growth factors, 
such as insulin-like growth factor 2 (IGF2), neurotrophin 3 (NT3), and platelet 
derived neurotrophic factor BB (PDGF-BB, Meier et al., 1999; Jessen and Mirsky, 
2005; Monk et al., 2015, Figure 2). 
During development, immature Schwann cells regulate the radial sorting of axons, 
that is the physiological process by which axons are separated based on their caliber. 
Bigger axons are radially segregated to the periphery (Feltri et al., 2016). After the 
segregation is complete, immature Schwann cells in contact with bigger axons 
stablish a 1:1 ratio with them, developing into pro-myelinating Schwann cells that 
subsequently become myelinating Schwann cells, that wrap these high diameter 
axons forming the myelin sheath. The others differentiate into non-myelinating 
Schwann cells, which envelope several small caliber axons, without forming a real 
myelin sheath, originating the so called Remak bundles (Monk et al., 2015, Feltri 
et al., 2016, Figure 2). Anyway, Schwann cells are characterized by remarkable 
plasticity, and can switch from a differentiation state to the other based on the 
situation, in particular during pathology (Feltri et al., 2016). 
Several transcription factors have been reported to be important in different 
differentiation phases (Svaren and Meijer, 2008; Salzer 2015, Figure 3). Sox2, NF-
kB and Egr1 are expressed in the first differentiation stages. When axons are 
segregated and Schwann cells start to differentiate towards the myelinating 
phenotype, NF-kB, Pou3f1 (Oct6/SCIP/Tst1), Pou3f2 (Brn2), Sox10, NFATc4, Yin 
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Yang (YY1), and Egr2/Krox20 are regulated and/or activated (Svaren and Meijer 
2008; Kao et al. 2009; He et al., 2010). In particular, when Schwann cells pass from 
the pro-myelinating to the myelinating phenotype, Pou3f1 and Pou3f2 are no more 
expressed, while Krox20 is up-regulated (Salzer, 2015). Krox 20 expression is 
promoted by Pou3f1, Pou3f2, NFATc4, YY1 and Sox10 (Jaegle et al. 2003; Kao et 
al. 2009; He et al. 2010). Also the sterol regulatory element-binding protein 
(SREBP) transcription factors are up-regulated and essential for myelination, in line 
with the up-regulation of lipids synthesis during myelination (Camargo et al., 
2009). The myelinating phenotype requires the contemporary expression of Krox20 
and Sox10, indeed conditional inactivation of one of the two genes leads to de-
differentiation (Decker et al. 2006; Bremer et al. 2011). 
 
Figure 3 – Main transcription factors involved in Schwann cell differentiation from the immature 
to the myelinating phenotype. Adapted from Salzer, 2015. 
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Krox20 is considered a master regulator of myelination (Topilko et al. 1994; Le et 
al. 2005b, Salzer, 2015). Indeed, its expression is cross-repressed with the 
expression of two important determinants of non-myelinating Schwann cells, Sox2 
and c-Jun (Le et al. 2005a; Parkinson et al. 2008; Jessen et al. 2015), and this cross-
regulation is fundamental in the differentiation of Schwann cells into one of the two 
states. 
Several extrinsic signals are also implied in the regulation of the myelination 
process. Among them, Neuregulin 1 (NRG-1), in particular the type III, is the key 
axonal molecule controlling myelination. Indeed, its expression level on axonal 
surface determines their myelination fate, being more expressed on high caliber 
neurons and lowly expressed on smaller ones (Taveggia et al., 2005). NRG-1 has 
an important role in virtually every aspect of Schwann cell lineage, including axon 
segregation during radial sorting (Taveggia et al., 2005; Michailov et al., 2004; 
Jessen et al., 2015, Raphael et al., 2011). There are six major classes of NRG-1 
(types I-VI), differing in the ectodomains splicing pattern (Salzer, 2015). Type III 
is the predominant type in peripheral axons (Mei and Xiong, 2008). NRG-1 exerts 
its action through the binding with the ErbB family of tyrosine kinase receptors, 
that in Schwann cells are mainly present in the form of the ErbB2/ErbB3 
heterodimer (Newbern and Birchmeier, 2010). Although NRG-1/ErbB signaling 
plays a fundamental role during the myelination process, it is not necessary to 
maintain myelination (Atanasoski et al., 2006; Fricker et al., 2011), nor for re-
myelination after injury, this because mature Schwann cells are able to secrete a 
soluble NRG isoform (NRG-1 type I) that promotes re-myelination in an autocrine 
fashion (Stassart et al., 2013). 
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Recently, the interaction between Lgi4 secreted by Schwann cells and Adam22 
expressed by axons has been demonstrated to be necessary for Schwann cells to 
differentiate beyond the pro-myelinating stage (Kegel et al., 2013), although the 
mechanism by which this interaction influences the myelination process is still 
unknown. 
Also the extra-cellular matrix has a role in the control of myelination. Different 
matrix components, such as laminin, are synthesized in Schwann cells and function 
as autocrine signals (Chernousov et al., 2008; Salzer, 2015). Laminin is a trimer 
formed by different α, β and γ chains. Laminin 2 is the main endoneurial form, 
while laminin 411 and 511 are minor forms (Chernousov et al., 2008). All this forms 
have been reported to promote radial sorting and myelination (Wallquist et al., 
2005; Yang et al., 2005). Laminin exerts these effects binding to different receptors 
expressed on the abaxonal (outer) membrane of the myelin sheath, such as β1-
integrins and dystroglycan (Salzer, 2015). 
Another mediator of the myelination process whose importance has lately been 
underlined is the G protein-coupled receptor GPR126 (Monk et al., 2009), that has 
been reported to be absolutely necessary for myelination and to play a role in 
Schwann cell development and in the radial sorting process (Mogha et al., 2013). It 
exerts its action modulating cyclic adenosine mono-phosphate (cAMP) intracellular 
levels, an essential signal for Schwann cell myelination, directly elevating cAMP 
levels or activating the protein kinase A (PKA) (Mogha et al., 2013; Glenn and 
Talbot, 2013a, b). Recent data show that laminin 211 is a physiological ligand of 
the receptor (Petersen et al., 2015). As for NRG-1/ErbB signaling, its activation is 
not necessary for the maintenance of myelination (Glenn and Talbot, 2013a, b). 
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Several evidence in literature support the hypothesis that an important role may also 
be played by other mediators, such as neuroactive steroids (as detailed below) and 
neurotrophins, some produced by Schwann cells, such as nerve growth factor 
(NGF), brain derived neurotrophic factor (BDNF), NT3, neurotrophin 4/5 (NT4/5) 
and glial cell line derived neurotrophic factor (GDNF, Chan et al., 2001; Cheng et 
al., 1999; Hoke et al., 2003; Schumacher et al., 2004). Numerous studies suggest 
that also neurotransmitters, such as purines, acetylcholine and GABA (detailed 
below) are involved in the peripheral nervous system biology and in Schwann cells 
functionality (Fields and Burnstock, 2006; Loreti et al., 2007; Stevens et al., 2004).  
Different intracellular pathways have been reported to be activated by the mediators 
mentioned above. Among them, the PI3K/Akt/mammalian target of rapamycin 
(mTOR) pathway seems to have a key role is Schwann cell development (Maurel 
and Salzer, 2000; Ogata et al., 2006). Indeed, hyper activation of PI3K leads to 
increased Schwann cell wrapping and hypermyelination of axons (Goebbels et al., 
2010) and these effects can be reverted with mTOR inhibitor rapamycin, suggesting 
that they are mediated by PI3K activation of the serine/threonine kinase Akt, which 
its responsible for mTOR activation (Goebbels et al., 2012; Salzer, 2015). NRG-1 
strongly activates mTOR, that, in accordance, is localized in sites that are in contact 
with the axon. Therefore, mTOR role in myelination is probably linked to its 
regulation of protein translation (Laplante and Sabatini, 2013; Salzer, 2015). 
Another intracellular pathway that has been linked to NRG-1 effects is the 
phospholipase C (PLC)-γ pathway (Kao et al., 2009). Indeed, NRG-1 binding to 
ErbB receptors directly activates PLC-γ, leading to increased intracellular calcium 
ion (Ca++) levels and subsequent calcineurin B activation, leading to a series of 
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intracellular events that activate Sox10 and Krox20 and up-regulate P0 expression 
(Kao et a., 2009; Lazarevic et al., 2009).  
Several data support the hypothesis that also the MAP kinase (MAPK) pathway has 
a critical role in the regulation of early Schwann cell differentiation, mediating the 
pro-myelinating activity of NRG-1. Indeed, it has been shown that the inactivation 
of this pathway mimics ErbB2 knockout (Grossmann et al., 2009). Genetic Erk1/2 
ablation during development leads to impaired differentiation of Schwann cells and 
defective myelination (Newbern et al., 2011). Conditional expression of an activate 
MAPK form (Mek1) leads to increased myelination even in cells deficient in ErbB3 
(Sheean et al., 2014). MAPK activates the pro-myelinating transcription factor YY1 
(He et al., 2010), but its effect in myelination may depend mainly on its stimulation 
of mTOR-dependent and independent protein translation. The fact that the 
activation of this pathway was able to rescue myelination, although the NRG-1 
activation of PI3K and PLC-γ was impossible because of ErbB3 absence suggests 
that the MAPK pathway may be able to activate the other two pathways or to grant 
a sufficient myelination level by itself (Sheean et al., 2014). 
Lastly, cAMP is known to promote and maintain Schwann cell myelinating 
phenotype (Stewart et al. 1991; Monje et al. 2010), likely with different 
mechanisms. Indeed, it converts Schwann cell response to NRG-1 from 
proliferation to differentiation (Arthur-Farraj et al., 2011) and increases Pou3f1 and 
Krox20 expression (Monuki et al., 1989: Kipanyula et al., 2013). Moreover, it 
activates cAMP-dependent PKA, which in turns activates by phosphorylation 
several transcription factors, such as NFkB and some members of the CREB family, 
such as CREB1, CREM and ATF1 (Tasken and Aandahl, 2004), which may have 
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an important role in cAMP-mediated effects on myelination (Arthur-Farraj et al., 
2011). 
When Schwann cells myelinate axons, they organize in a longitudinally and radially 
polarized fashion, with distinct membrane domains, specific arrays of proteins and 
communicating sets of cytoplasmatic compartments (Pereira et al., 2012, Salzer, 
2015). Longitudinal polarity leads to the organization of the myelinated fiber into 
nodal, paranodal, juxtparanodal and internodal compartments, while radial polarity 
consists in the presence of adaxonal (inner) and abaxonal membrane surfaces. The 
adaxonal membrane comprises the paranodal, juxtparanodal and internodal domain, 
with the latter being by far the larger, around 99% of myelinating Schwann cells. 
Proteins typical of this area are the myelin associated glycoprotein (MAG), 
CADM1 and CADM4 (Maurel et al. 2007; Spiegel et al. 2007).  
The compacted myelin sheath is comprised between the adaxonal and abaxonal 
membranes. It derives from Schwann cell wrapping around axons. As previously 
mentioned, myelin provides electrical isolation to axons, allowing saltatory 
conduction. Observing electron microscopy images of compact myelin, it is 
possible to appreciate the alternation of intraperiod lines and major dense lines. The 
first are the areas where there is apposition of extracellular leaflets, the latter are the 
areas of cytoplasmic leaflets apposition (Salzer, 2015, Figure 4). 
Myelin is characterized by an extremely high plasma membrane lipid content, 
roughly 70%, being particularly enriched in galactosphingolipids, saturated long-
chain fatty acids and, in particular, cholesterol, that is essential for the assembly of 
the myelin sheath (Saher and Simons, 2010). 
24 
 
The main protein components of compact myelin, fundamental for the compaction 
process, are myelin protein zero (P0), myelin basic protein (MBP) and the 
peripheral myelin protein of 22 KDa (PMP22). P0 is a transmembrane glycoprotein, 
which promotes the apposition of extracellular leaflets (Filbin et al. 1990; Shapiro 
et al., 1996). In cooperaration with MBP, it promotes also intracellular leaflets 
apposition, giving major dense lines (Martini et al., 1995, Figure 4). 
 
Figure 4 – Basic structure of uncompacted and compacted myelin sheath. The main myelin proteins 
P0, MBP and PMP22 contribute to the compaction process and to the formation of the myelin sheath. 
Adapted from Salzer, 2015.  
 
Among compact myelin sheaths layers there are clefts with thin cytoplasmic insert, 
known as Schmidt-Lanterman incisures. These clefts have long been thought to 
provide a communication conduit between inner and outer adjacent membranes 
(Balice-Gordon et al., 1998). However, recent studies suggest they may also be site 
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of autocrine signaling (Heller et al., 2014). They are enriched in the tyrosin-kinase 
Src (Terada et al., 2013) and in many adhesion molecules present in the adaxonal 
membrane, such as MAG and CADMs (Maurel et al., 2007; Spiegel et al., 2007), 
suggesting a common topology. 
Mutations in genes encoding for myelin proteins are an important cause of 
hereditary peripheral neuropathies. Indeed, mutations to P0 and PMP2, for 
example, can originate the Charcot-Marie-Tooth disease (CMT) in its different 
variants (Martini et al., 1995; Shy, 2006; Suter and Scherer, 2003; Berger et al., 
2006; Pareyson et al., 2013).   
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PERIPHERAL NEUROPATHIES  
 
GENERAL CONCEPTS 
 
Peripheral neuropathies are a heterogeneous group of pathologies, characterized by 
alterations of peripheral nerves structure or function. These highly debilitating 
pathologies present a high prevalence (14,8%) in Western countries, and their 
incidence grows with age, being particularly high in people affected by 
dysmetabolic diseases (Gregg et al., 2004). 
From a patho-physiological point of view, peripheral neuropathies can be classified 
as hereditary or acquired, axonal or demyelinating. Hereditary peripheral 
neuropathies, which can be either axonal or de-myelinating, are very common 
neurological diseases, often with high incidence (Saporta and Shy, 2013). Some 
examples are the CMT, whose prevalence, 1:2500, is very high (Braathen et al., 
2011), or the hereditary motor and sensory neuropathy (HMSN, Lupski et al., 2001; 
Dyck et al., 1993). Acquired peripheral neuropathies can derive from chronic (such 
as diabetes, Singh et al., 2014) or infective diseases (such as leprosy, Masaki et al., 
2013), environmental toxins (Little and Albers, 2015), alcoholism (de la Monte and 
Kril, 2014), nutritional deficit (D’Amour and Butterworth, 1994), autoimmune 
diseases (Bourque et al., 2015) but they are often due to iatrogenic causes (Sposato 
and Faustinoni, 2014) or traumatic events, most commonly attributable to direct 
mechanical trauma, and less frequently to surgical resection secondary to tumor 
excision (Faroni et al., 2015).  
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The symptomatology can be very heterogeneous, depending on the kind of nervous 
district (sensitive, motor or vegetative) that is involved. The main debilitating 
conditions include lack of motor control and proprioceptive sensitivity. However, 
some common clinical manifestations can be identified in the presence of sensory 
symptoms (like numbness or tingling), weakness, autonomic symptoms (such as 
satiety, impotence, orthostatic hypotension and sweat abnormalities), or the onset 
of neuropathic pain (Watson and Dyck, 2015). The etiology of peripheral 
neuropathies is generally unknown in 50% of the cases (Imreovà and Pura, 2005). 
Therefore, therapies are based mainly on symptomatic and palliative 
pharmacological treatments (Watson and Dyck, 2015), making the identification of 
more specific pharmacological targets or alternative bioengineered approaches a 
strong medical need. 
 
NEUROPATHIC PAIN 
 
Neuropathic pain is one of the main clinical sign of peripheral neuropathies. 
Peripheral neuropathic pain derives from lesions to the peripheral nervous system, 
which can be caused by mechanical trauma, metabolic disease, neurotoxins, 
infections or tumor invasion, and may determine different physiological changes 
both in peripheral and central nervous systems (Dworkin et al., 2003, Woolf and 
Mannion, 1999). Neuropathic pain is classified and treated on the basis of the 
underlying disease (Dworkin et al., 2007).  
The two major general contributors in the development of neuropathic pain seem 
to be the altered balance between compensatory and de-compensatory responses of 
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the nervous system to damage and the genetic background, which seems able to 
have a role in the establishment of neuropathic pain (Costigan et al., 2009). 
A typical characteristic of neuropathic pain is the absence of an identifiable 
stimulus. Pain arises spontaneously from ectopic action potentials in nociceptive 
pathways, without a stimulus at the level of peripheral terminals. Several evidence 
suggest that ectopic activity is generated mainly in primary sensory neurons. 
Indeed, after peripheral nerve damage, spontaneous activity may originate at 
different sites, such as the neuroma (that is the site of injury with aborted axon 
growth), DRG cell bodies (Amir et al., 2005), and uninjured afferent fibers near the 
lesion (Wu et al., 2002). The spontaneous pain can derive both from ectopic activity 
in nociceptors (Bostock et al., 2005) and from low-threshold large myelinated 
afferents (Campbell et al., 1988). 
Even if several approaches are used or are currently studied in order to promote 
nerve regeneration (as detailed below), most of the times none of these methods 
leads to satisfactory nerve repair, and current therapies are mainly addressed to the 
control of painful symptoms rather than to treat nerve degeneration and/or to 
promote regeneration. Therefore, new strategies that simultaneously promote nerve 
regeneration controlling neuropathic pain are needed. 
 
NERVE REGENERATION 
 
It is well established that, differently from central nervous system neurons, 
peripheral nerves can regenerate after a damage. It is also known that Schwann cells 
support nerve regeneration, while oligodendrocytes of the central nervous system 
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do not (Fenrich and Gordon, 2004; Faroni et al., 2015; Taveggia, 2016). Indeed, 
when axons lose contact with their cell bodies after a lesion, axonal transport in the 
stumps stops, starting the Wallerian degeneration process. During this process, both 
axon and myelin in the distal stump degenerate, and macrophages are recruited in 
order to contribute to debris clearance (Chen et al., 2007, Figure 5).   
Schwann cells shift from the myelinating to the non-myelinating state and start to 
proliferate and migrate (Fu and Gordon, 1997; Gaudet et al., 2011). During this 
transition, Schwann cells express many regeneration-associated genes, such as 
neurotrophic factors (NGF, BDNF, GDNF, pleiotrophin, Boyd and Gordon, 2003; 
Hoke et al., 2006) and transcription factors like Notch and c-Jun (Jessen and 
Mirsky, 2005; Jessen et al., 2008; Fontana et al., 2012, Figure 5). Also the neuronal 
compartment undergoes some modifications, reflecting a transition from a 
transmission to a growth mode, in a process called chromatolysis (Lieberman, 1971; 
Gordon and English, 2015). Pro-regeneration genes, like tubulin and actin, are up-
regulated, whereas transmission-related genes, such as acetylcholine and choline 
acetyltransferase are down-regulated (Fu and Gordon, 1997; Zigmond, 2012). 
During the regeneration process, all axons that are still in contact with their cell 
body are reported to emit sprouts (Gordon and English., 2015). A study performed 
using transgenic mice expressing green fluorescent protein in their neurons has 
shown that after seven days of regeneration, in proximity of the surgical site mice 
presented a highly disorganized extracellular matrix with few Schwann cells 
(Witzel et al., 2005). Indeed, laminin becomes organized after 10 days circa, and 
only after that Schwann cells can move into the surgical site and align forming the 
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bands of Burgner, which guide axon sprouts through the surgical repair site (Gordon 
and English, 2015, Figure 5). 
 
Figure 5 – Schematic representation of the events following nerve damage. Wallerian degeneration. 
Following injury, Schwann cells detach from the axons, start proliferating and help the recruited 
macrophages to clear the cellular and myelin debris. At the same time, expression of stimulating 
factors by SCs create a favorable environment for nerve regrowth towards the target organ. Adapted 
from Faroni et al., 2015. 
 
After injury, the regeneration outcome relates to the age of patient, the mechanism 
of injury and, in particular, to the proximity of the injury to the nerve cell body 
(Faroni et al., 2015). Distal digital nerve injuries, indeed, have usually much better 
outcome than proximal brachial plexus avulsions, which may be functionally 
devastating, leading to serious problems to perform activities of daily living, as well 
as preventing return to work (Brushart, 2011). 
The surgical treatment of choice in case of nerve injury is microsurgical repair by 
tensionless epineurial sutures, and in case the gap distance prevents end-to-end 
suturing, autologous nerve grafting remains the gold standard (Millesi, 2007). An 
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important factor is time, since delayed repair demonstrated to be significantly 
detrimental to satisfactory sensory and motor recovery (Jivan et al., 2009, Gordon 
et al., 2011). Even if, in recent years, the knowledge of peripheral nerve injury 
patho-physiology strongly improved, clinical outcomes are still often poor 
(Lundborg, 2000; Faroni et al., 2015). There is therefore a strong need for the 
identification of new strategies to promote nerve regeneration, such as nerve 
guidance conduits, pharmacotherapy and cell therapy (Faroni et al., 2015).  
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THE GABAERGIC SYSTEM 
 
GABA  
 
γ-amino butyric acid (GABA) is the main inhibitory neurotransmitter of the nervous 
system. After its first characterization in 1950 (Roberts and Frankel, 1950) many 
studies demonstrated its role in the patho-physiology of the nervous system. 
Glutamic acid decarboxylase (GAD), the enzyme responsible for GABA synthesis, 
is not equally distributed in the central nervous system. Indeed, it is present in 
higher concentration in districts like substancia nigra, globus pallido, 
hypothalamus, hippocampus, quadrigeminal bodies, cerebral cortex, cerebellum 
and the spinal cord. Lower concentrations have been detected in the pons, the 
medulla oblongata and the white matter (Erlander et al., 1991). GAD synthesizes 
GABA through glutamate decarboxylation in a highly specific interaction. The 
enzyme requires pyridoxal phosphate (PLP) as a cofactor, and so can be inhibited 
using PLP antagonists, such as hydrazinic compounds. GAD is present in different 
isoforms, the main two being GAD 67 and GAD 65 (Erlander et al., 1991). GAD 
67 is evenly distributed throughout the cell, while GAD 65 is mainly localized in 
the cytoplasm of axon terminals (Pinal and Tobin, 1998).  
After synthesis, GABA is stored in vesicles by the action of a specific transporter 
coupled to a vesicular protonic pump. GABA release in the synaptic space requires 
vesicles to fuse with plasma membrane (Figure 6). This event can occur 
spontaneously or following de-polarization caused by Ca++ influx (Hablitz et al., 
2010).   
33 
 
Once released, GABA can bind its specific receptors (described later) or it can go 
towards re-uptake by neurons and glia, by the action of specific transporters GAT1-
3, that co-transport GABA with sodium (Na+) and chloride (Cl-) ions (Carver and 
Reddy, 2013, Figure 6). There is evidence suggesting that the glial transporter is 
more important in the maintenance of low GABA synaptic levels. Once re-uptaken 
by neurons and glia, it is degraded by the enzyme GABA transaminase (GABA-T), 
present both in pre- and post-synaptic neurons and in glia, that catalyzes its de-
amination to succinate semialdehyde (SSA, Figure 6). This chemical compound is 
subsequently oxidized by a NAD-dependent succinate semi aldehyde 
dehydrogenase leading to the formation of succinic acid, which enters Krebs cycle. 
GABA-T transfers the amino group from GABA to a molecule of α-ketoglutarate, 
leading to the formation of new glutamate (Petroff, 2002; Carver and Reddy, 2013). 
GABA exerts its effects through the binding with its receptors, the ionotropic 
receptor GABA-A and the metabotropic receptor GABA-B. 
 
GABA-A RECEPTORS 
 
GABA-A receptors are hetero-oligomeric receptors formed by different 
combinations of 5 subunits. GABA binding with these receptors leads to the 
opening of a Cl- channel that usually leads to an inward current inducing hyper-
polarization. 
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Figure 6 – Representation of a GABAergic synapse. GAD converts glutamate to GABA, that is 
stored in vesicles before release. Once released, it can bind one of its receptors (in this example, a 
post-synaptic GABA-A receptor), or it can go towards GAT-mediated re-uptake in neuronal and 
glial cells, when it is converted to SSA by the action of GABA-T. Adapted from Carver and Reddy, 
2013.    
 
However, in some cases, the Cl- channel opening leads to depolarization; this 
happens in neuronal cells (mostly immature) which present an intracellular Cl- 
concentration higher than the extracellular one (Lu et al., 2014).  
Nineteen genes encoding for GABA-A subunits have been identified so far: α1–α6, 
β1–β3, γ1–γ3, δ, ε, π, τ, ρ1–ρ3 (Fritschy and Panzanelli, 2014). Different subunit 
composition leads to the formation of different receptors which differ in subcellular 
localization, distribution and function. The majority of GABA-A receptors are 
formed by the combination of 2 α, 2 β and a γ, δ or ε subunit (Boileau et al., 2005; 
Olsen and Sieghart, 2008; Patel et al., 2014; Jacob et al., 2008, Figure 7a). 
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Figure 7 – a) Typical subunit composition of most GABA-A receptors and b) typical subunits 
composition and localization of classical synaptic and extra synaptic receptors. Adapted from Jacob 
et al., 2008 and Reddy, 2011. 
 
An important distinction can be made between synaptic and extra synaptic GABA-
A receptors. The first are localized at post-synaptic terminals, and mediate the 
classical phasic inhibition upon GABA release from pre-synaptic terminals. The 
second receptor sub-type is instead localized aside synaptic position, and is 
responsible for tonic GABA-A inhibition (Belelli et al., 2009; Reddy, 2011, Figure 
7b). An interesting characteristic of this latter receptors, in particular the δ subunit-
containing ones, is that, at least in some specific brain areas, they resulted to be 
particularly responsive to neuroactive steroids (Belelli et al., 2002; Wohlfarth et al., 
2002. Mihalek et al., 1999). 
In general, β subunits composition is not particularly indicative of the synaptic or 
extra-synaptic nature of a given GABA-A receptor. α1, α2, α3 and γ2 subunits 
typically form synaptic receptors, while α4, α5, α6 are typical extra-synaptic 
receptor subunits, with the γ2 subunit often substituted by δ (Fritschy and 
Panzanelli 2014). In particular, it is generally correct to say that a GABA-A receptor 
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that presents a δ subunit is extra-synaptic, but not all extra-synaptic receptors 
present the δ subunit (Belelli et al., 2009). 
Tonic inhibition is generally thought to be due to receptor activation by ambient 
GABA. However, there is evidence that spontaneous opening of GABA-A 
receptors may contribute to most of tonic currents recorded in the dentate gyrus 
(Wlodarczyk et al., 2013). 
Several extra-synaptic receptors, presenting the δ subunit, have high affinity for 
GABA and mediate most of the actions of neuroactive steroids, in particular the 
progestogen allopregnanolone (described in more detail below), modulating brain 
activity when their synthesis is up-regulated, such as in condition of stress, delivery 
and ethanol intoxication (Sarkar et al., 2011; Carver and Reddy, 2013). They 
present a specific pharmacological profile, indeed they are modulated by the super 
agonist gaboxadol, but are insensitive to classical benzodiazepines (Mortensen et 
al., 2010).  
Some data suggest that surface expression of these receptors is modulated, in 
dentate gyrus and thalamus, by PKA and protein kinase C (PKC) activity, targeting 
α4 containing GABA-A receptors (Connelly et al., 2013; Tao et al., 2013). In 
particular, cell surface expression of these receptors has been reported to be 
mediated by α4 subunit’s Ser443 phosphorylation mediated by PKC (Abramian et 
al., 2010).  
Although α4/β/δ receptors seem to be the most prominent extra synaptic population, 
also α5 containing GABA-A extra-synaptic receptors seem to be expressed in the 
hippocampus, olfactory bulb and cerebral cortex. In these receptors, the α5 subunit 
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is most probably linked with β3 and γ2 subunits. They respond to diazepam but are 
insensitive to zolpidem.  
Other diazepam-sensitive (γ2 containing) receptors have been proved to be located 
extra-synaptically. In particular, α3-containing extra synaptic receptors have been 
detected in the amygdala and in the inferior olivary nucleus (Marowsky et al., 2012; 
Devor et al., 2001), even if most α3 containing receptors have been proved to be 
synaptic (Studer et al., 2006; Schneider Gasser et al., 2007; Notter et al., 2014). The 
mechanisms that determine synaptic or extra-synaptic localization of these 
receptors are not yet completely understood, probably involving interaction with 
gephryn. Something similar has been reported to happen also with α5-containing 
GABA-A receptors, which can locate synaptically in the hippocampal formation 
(Serwanski et al., 2006). Extra-synaptic localization in this case seems to be 
correlated with interaction with radixin, an ezrin-radixin-meosin family member 
which interacts with the cytoskeleton (Loebrich et al., 2006).   
Different studies, in particular using immunoprecipitations techniques, allowed to 
determine GABA-A subunits composition in several regions of the central nervous 
system. Even if the most common stoichiometric ratio is two α, two β and one γ, δ 
or ε, there is also evidence suggesting the existence of receptor containing only α 
and β subunits, or with different stoichiometry (such as 2 α, 1 β and 2 γ or 2 α, 1 β 
and 2 ε, Jones and Henderson, 2007). The most classical GABA-A receptor 
composition, showing the pharmacological profile of native receptors, presents two 
α, two β and one γ2 subunits. Α and β subunits can be identical or different among 
them (Fritschy and Panzanelli, 2014). Γ2 subunit can be substituted by γ1, γ3 (not 
common in the central nervous system), δ and ε subunits. So far, at least 36 different 
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GABA-A subtypes have been identified in the central nervous system (Olsen and 
Sieghart, 2008).  
Immunohistochemical studies on the distribution of 10 subunits (α1-α6, β2, β3, γ2 
and δ, Fritschy and Mohler, 1995; Nusser et al., 1999; Peng et al., 2002; Chandra 
et al., 2006; Hortnagl et al., 2013) suggest that, in general, the six α subunits may 
correspond to distinct GABA-A subtypes (even if a substantial fraction of GABA-
A receptors may contain two different α subunits, Balic et al., 2009) with a specific 
distribution pattern, partially overlapping with others. β2 and β3 subunits mostly 
overlap with α1 and α2, while the β1 subunit is expressed at lower levels in different 
brain regions (Fritschy and Panzanelli, 2014). Among γ subunits, γ2 is ubiquitously 
expressed, while γ1 has a specific expression pattern, mainly restricted to 
hypothalamus, amygdala, basal ganglia and the inferior olivary nucleus. The δ 
subunit, as already mentioned typical of extra-synaptic receptors, is co-expressed 
with the α4 subunit in the forebrain and with the α6 in the cerebellum. 
More specific distribution data are available for some regions, such as the 
hippocampus (in particular the CA1 subfield), the neocortex, the olfactory bulb, 
parts of the thalamus, the cerebellum and the spinal cord dorsal horn.  Analyzing 
staining patterns, it is sometimes possible to distinguish between synaptic and extra-
synaptic receptors. The first ones appear as brightly stained clusters, co-localizing 
with post-synaptic markers like gephryn and neuroligin 2 (NL2). The latter ones do 
not form clusters, with uniform staining, suggesting widespread distribution on 
dendritic branches. Moreover, they do not co-localize with gephryn (Fritschy and 
Panzanelli, 2014). 
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Even if not clearly detectable from immunohistochemical studies, strong functional 
evidence suggests that there is a sub-population of receptors localized in axonal pre-
synaptic terminals (Grasshoff et al., 2007; Trigo et al., 2008; Long et al., 2009; 
Witschi et al., 2011), which may represent a particular subset of extra-synaptic 
receptors with specialized functions. They are supposed to have a role in the 
modulation of potential transmission, neuronal synchronization, transmitters 
release and presynaptic afferent depolarization (Trigo et al., 2008; Long et al., 2009; 
Ruiz et al., 2010; Wakita et al., 2013).  
Lastly, data obtained analyzing the mRNA expression of 18 different GABA-A 
subtypes in mouse brain allow to sort out the GABA-A subunits distribution in the 
central nervous system, once combined with previous data (Fritschy and Panzanelli, 
2014). This data confirms previous studies in the distribution of more abundant 
subunits (α1–α6, β1–β3, and γ2, Laurie et al., 1992; Wisden et al., 1992), but also 
give new insights on lowly expressed ones, such as ε, whose expression seems to 
be mostly limited to amygdala, basal forebrain, locus coeruleus and other 
noradrenergic sites.  Ρ1 and ρ2 subunits (which form a subtype of GABA-A 
receptors once known as GABA-C) are expressed only on the superficial layers of 
the superior colliculus, and the σ subunit is undetectable in the adult brain.  
Different studies conducted with knock-in mice for different GABA-A subunits 
helped to better understand their specific role in GABA-A receptors assembly. The 
deletion of specific subunits proved to be able to modify the expression pattern of 
other subunits, indicating the possible presence of compensatory mechanisms. For 
example, α1 knockout led to up-regulation of both α2 and α3 subunits (Kralic et al., 
2006; Zeller et al., 2008). δ knockout, instead, led to an up-regulation of α4 subunit 
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in association with γ2, leading also to altered subcellular distribution (Peng et al., 
2002). 
Generally, there is no simple replacement of the missing subunit with other ones, 
in particular in neurons which express both synaptic and extra synaptic receptors. 
Indeed, deletion of synaptic α subunits may lead to pot-synaptic receptors 
disappearance and loss of post-synaptic currents. When this happens, extra synaptic 
currents can remain unaltered or be increase (Kralic et al., 2006; Peden et al., 2008), 
suggesting that the inability of α4 receptors to cluster at post-synaptic sites is not 
linked to competition with other receptors. Also, in neurons expressing different 
sub-types of synaptic receptors, there are specific rearrangements but without 
replacement of the missing subunit. This phenomenon was observed for example 
in CA1 pyramidal cells of knockout mice for the α2 subunit, where all GABA-A 
receptors were unchanged in perisomatic synapses, but disappeared from the initial 
segment of the axon (Panzanelli et al., 2011). In some sporadic cases, however, 
some forms of compensative mechanisms have been reported. For example, in 
thalamic reticular neurons of knockout mice for the α3 subunit there is an apparent 
loss of post-synaptic GABA-A receptors, but post-synaptic currents were higher 
than in control mice (Schofield et al., 2009). 
Taken together, these data suggest that different GABA-A subtypes, defined by 
their different subunit composition, have different roles and characteristics, being 
not interchangeable within a given neuronal type (Fritschy and Panzanelli, 2014).  
Several studies have been conducted with a model of knock-in mice (H101R), 
ideated to remove the diazepam binding site at the α-γ interface of the pentamer 
without altering other features (Rudolph et al., 1999; Low et al., 2000; Crestani et 
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al., 2002; Yee et al., 2005). Behavioral analysis of different variants of the model 
revealed different loss of specific diazepam effects, allowing a better understanding 
of each subunits contribution to diazepam effects. Evidence from these experiments 
suggests that sedative effects depend on α1 containing receptors, while anxiolysis 
is mediated by allosteric modulation of α2 containing receptors, with a partial 
contribution from α3-containing ones in stressful conditions (Rudolph and Mohler, 
2004). As previously stated, it is in generally complicated to distinguish different 
GABA-A receptors based on β subunits composition, mainly because each β 
subunit can be associated with different α ones. However, some data suggest that 
β3-subunit containing receptors are responsible for the action of intravenous 
general anesthetics and of some effect of pentobarbital (Jurd et al., 2003, Zeller et 
al., 2007). Moreover, neuron-specific deletion of the subunit decreases survival of 
most mutant mice after early post-natal age (Ferguson et al., 2007). 
GABA-A receptors have also been found to be expressed in glial cells, including 
astrocytes (Berger et al.,1992; Israel et al., 2003; Kettenmann et al.,1987), 
oligodendrocytes and Schwann cells. GABA-A expression in Schwann cells is 
detailed below and in the results. Both oligodendrocyte precursor cells and mature 
oligodendrocytes have been reported to express the GABA-A receptor (Hoppe and 
Kettenmann 1989; Von Blankenfeld et al., 1991; Berger et al., 1992). A recent study 
analyzed the subunits composition of GABA-A expressed in mature 
oligodendrocytes cultivated alone or in co-culture with DRG neurons. Combining 
pharmacological and immunofluorescence studies, the authors suggest that GABA-
A receptors in oligodendrocytes do not express the δ subunit (as suggested by the 
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low sensitivity for allopregnanolone), suggesting that the most important subunits 
present in oligodendrocytes are α3, β2, β3, γ1 and γ3 (Arellano et al., 2016).  
 
GABA-B RECEPTORS 
 
The GABA-B receptor was initially identified by in the early 80’s (Bowery et al., 
1980). In the following years, different studies contributed to demonstrate its 
presence in mammalians central nervous system, both in neurons and glia (Kozlov 
et al., 2006; Serrano et al., 2006; Kuhn et al., 2004; Luyt et al., 2007). In particular, 
some pharmacological and biochemical studies showed that these receptors were 
not responsive to treatments with bicuculline or GABA-mimetics, but were 
specifically activated by GABA and β-p-clorofenil-GABA or baclofen. Moreover, 
it was demonstrated that GABA-B receptors are not coupled to Cl- channels and are 
not responsive to barbiturates or benzodiazepines.   
At synaptic level, GABA-B receptors are localized both at pre- and post-synaptic 
level (Figure 8). Pre-synaptic localization is much more common, where GABA-B 
receptors play an important role in the regulation of the release of different 
receptors, including GABA itself. They are commonly called auto-receptors when 
localized on GABAergic pre-synaptic terminals, and hetero-receptors when 
localized on other terminals (Gassmann and Bettler, 2012).   
Two sub-types of the GABA-B receptor have been identified so far, named GABA-
B1 and GABA-B2. GABA-B1 has been characterized at least in 3 different 
isoforms, named GABA-B1a, b, and c (Kaupmann et al., 1997, Isomoto et al., 1998, 
Pfaff et al. 1999, Gassmann and Bettler, 2012). The second sub-type, named 
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GABA-B2, was identified simultaneously by different groups (Jones et al., 1998; 
Kaupmann et al., 1998; White et al., 1998; Kuner et al., 1999). Different studies 
made using recombinant receptors have clearly shown that the active form of the 
GABA-B receptor is the GABA-B1/GABA-B2 heterodimer, with the two subunits 
in a 1:1 stoichiometric ratio (Charles et al., 2003). Different models of mice lacking 
the GABA-B1 gene confirmed that it is essential for GABA-B assembly (Schuler 
et al., 2001). The interaction between the two subunits takes place at their carboxyl-
terminal domains, leading to the formation of a α-helix coiled coin structure. The 
GABA-B1 subunit is responsible for the binding with GABA and other specific 
ligands, while GABA-B2 is responsible to the functionality of the heterodimer, for 
the co-regulation of some transcription factors (such as ATF1 and CREB-2) and for 
the interaction with auxiliary subunits, belonging to the KCTD family, which bind 
to GABA-B2 as part of a stable receptor complex at the cell surface (Charles et al., 
2003; Gassmann and Bettler, 2012).  
GABA-B1 isoforms are distributed throughout the neuronal and glial compartments 
in the brain, in the spinal cord (Charles et al., 2001; Margeta-Mitrovic et al., 1999) 
and in DRG (Campbell et al., 1993; Charles et al., 2001; Dolphin and Scott, 1986; 
Magnaghi, 2007; Towers et al., 2000), suggesting the involvement of GABA-B 
receptors in sensory functions (Bowery, 1993; Fromm, 1989; Hering-Hanit and 
Gadoth, 2001; Sindrup and Jensen, 2002).  
GABA-B receptors belong to the G-protein coupled receptor (GPCR) family. When 
an agonist binds to the receptor, it induces the activation of an inhibitory G protein, 
belonging to the Gi/G0 family, which leads to the inhibition of the enzyme adenylyl 
cyclase. This inhibition causes a reduction in cAMP levels, with reduced PKA 
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activity and, therefore, reduced phosphorylation levels of PKA-dependent 
transcription factors (Steiger et al., 2004) and kinases (Diversè-Pierluissi et al., 
1997; Ren and Mody, 2003; Gassmann and Bettler, 2012, Figure 8).  
These processes are able to modulate neuronal excitability and the release of 
neurotransmitters. GABA-B activation may also cause a reduced Ca++ and increase 
potassium ion (K+) conductance. The effect on Ca++ is more important at pre-
synaptic level, involving mainly voltage-gated calcium channels (VGCC, Figure 
8). Reduced Ca++ influx in the cell may be the main mechanism responsible for the 
inhibition of mediators’ release, slowing vesicles formation (Sakaba and Neher, 
2003). Instead, the effect on K+ currents is modulated at post-synaptic level. Indeed, 
the activation of post-synaptic GABA-B receptors leads to a slow inhibitory post-
synaptic potential (IPSBB) through the activation of K
+ GIRK channels, whose 
opening causes membrane hyper-polarization (Gassmann and Bettler, 2012).  
The regulation of these channels is modulated by β and γ subunits of the activated 
G protein (Gassmann and Bettler, 2012, Figure 8). This process is limited to the cell 
membrane and independent from second messengers, being able to mediate these 
effects just few seconds after the receptor activation. 
GABA-B receptors activity seems to be very important in the modulation of normal 
physiological processes of the central nervous system. For example, studies 
performed using knockout mice for the receptor have shown that he animals were 
hyper-active and presented epileptic episodes (Bettler and Tiao, 2006, Kornau, 
2006). 
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Figure 8 – Pre-synaptic (a) and post-synaptic (b) GABA-B receptors. Both at pre- and post-synaptic 
level, GABA-B effects are mediated both by the αi/0, β and γ subunits of the G protein coupled to 
the receptor. Those actions are mainly mediated by adenylyl-cyclase down-regulation, but also by 
modulation of Ca++ and K+ channels. Adapted from Gassmann and Bettler, 2012. 
 
Some results obtained with ultra-structural studies show how most GABA-B 
receptors are present in excitatory synapses, such as glutamatergic ones (Lacey et 
al., 2005; Kulik et al., 2006, Gassmann and Bettler, 2012). Some studies, indeed, 
show how some fibers are able to release GABA following an increase in excitatory 
transmission, strengthening the hypothesis that it can be co-released by 
glutamatergic synapses as a control mechanism of their activity (Walker et al., 
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2002; Gutierrez, 2002). Another study suggests that GABA-B receptors on 
glutamatergic synapses may also be activated by the GABA released by dendritic 
cells (Zilberter et al., 1999). 
Most cerebral neurons co-express both GABA-B 1a and 1b isoforms. They derive 
from the same gene after different splicing of the promoter (Steiger et al., 2004; 
Gassmann and Bettler, 2012). From a structural point of view, the two isoforms are 
different in their ectodomains at the level of a couple of sushi domains (Blein et al., 
2004). Even if there are no functional or pharmacological differences among the 
two isoforms in vitro, they generate different responses in vivo. This may be due to 
different post-transcriptional modifications the two subunits may face. Indeed, it is 
reported that GABA-B mediated responses are regulated by phosphorylation 
(Couve et al., 2002; Kuramoto et al., 2007) and by proteins associated to the 
receptor (Perroy et al., 2003; Pontier et al., 2006; Kanaide et al., 2007; 
Balasubramanian et al., 2007). The two isoforms functions were analyzed using 
mice genetically modified to express just one of them (Perez-Garci et al., 2006; 
Vigot et al., 2006; Shaban et al., 2006). These studies suggested that the most 
significant difference is GABA-B1a presence in glutamatergic terminals as shown 
in hippocampal and neocortical pyramidal cells (Vigot et al., 2006; Shaban et al., 
2006). These data were confirmed by imaging studies, localizing GABA-B1a in 
CA3 pyramidal neurons (Vigot et al., 2006). It is possible that sushi domains, being 
the only different region among the two subunits, may be able to determine the 
different axonal localization of the two isoforms.         
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GABAERGIC SYSTEM IN THE PERIPHERAL NERVOUS SYSTEM 
 
Some studies from different research groups, performed between the 1970’s and 
80’s, provided indication that the GABAergic system is present and active in the 
peripheral nervous system. Binding studies showed the GABA receptors both in 
myelinated and unmyelinated fibers as well as in Schwann cells (Brown and Marsh, 
1978; Brown et al., 1979; Morris et al., 1983; Olsen et al., 1984; Nagai et al., 1998).  
More recent studies demonstrated that peripheral nerves, and Schwann cells in 
particular, express different GABA-A (α2-3, β1-3, γ2) and GABA-B (1a, 1b and 2) 
subunits (Melcangi et al.,1999; Magnaghi et al., 2001,2006). As already mentioned, 
Schwann cells are able to synthesize GABA through the action of the GAD67 
enzyme. The same studies provided evidence that GABA can control its own 
synthesis via a GABA-A mediated mechanism through the MAPK/CREB pathway 
activation (Magnaghi et al., 2009, 2010).  As better detailed below, the GABA-A 
receptor has also an important role in the mediation of several action of the 
neuroactive steroid allopregnanolone, including the modulation of myelin proteins 
expression, Schwann cell proliferation and the trafficking of the glutamate EAAC1 
transporter (Magnaghi et al., 2001; Perego et al., 2012).  
In recent years, some evidence proved the importance of the GABAergic 
systempresent in Schwann cells in the neuron-glia interaction and in the patho-
physiology of the peripheral nervous system. In particular, two papers (Magnaghi 
et al., 2008; Faroni et al., 2014), demonstrated a role for the GABA-B receptor in 
peripheral myelination and in pain processing mechanisms. Both GABA-B1 total 
knockout mice (Magnaghi et al., 2008) and conditional knockout mice, which 
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present a selective deletion of the GABA-B1 receptor only in Schwann cells (P0-
CRE_GABA-B1fl/fl mice, Faroni et al., 2014), present indeed alterations in pain 
response to thermal and mechanical stimuli and changes both in Schwann cell 
autonomous and non-autonomous parameters. Specifically, GABA-B1 conditional 
knockout mice were characterized by morphological alteration, with a significant 
increase of the percentage of irregular fibers and signs of unloose wrapping of the 
myelin sheath, revealing defective myelination. At the molecular level, the gene 
expression of myelin proteins P0 and PMP22 was increased, and P0 expression was 
higher in conditional knockout animals also at the protein level in 3 months old 
animals. The study of intracellular pathways revealed that in three months old 
animals the NRG-1 typeIII-ErbB2/ErbB3-Erk2 pathway, that, as already 
mentioned, is considered one of the main pathway involved in myelination control 
(Feltri et al., 2016; Salzer, 2015; Taveggia, 2016), are modulated. This evidence 
strongly suggests a role for GABA-B receptors in its modulation. A detailed 
analysis of these fibers type showed that conditional knockout mice presented an 
increased percentage of small axons and a higher presence of Remak bundles and 
unmyelinated fibers, pointing to an increased presence of C fibers, mostly involved 
in pain transmission. Accordingly, the number of small cell bodies in DRG, from 
which these fibers originate, resulted to be increased. Those morphological 
evaluations were in line with observed alterations in pain sensitivity, indeed both 3 
and 6 months old animals resulted to be hyperalgesic following thermal stimuli, and 
younger animals also shown mechanical allodynia. Interesting, in a paper in which 
a similar model was used to obtain a selective knockout of GABA-B receptors in 
DRG, only slight modifications in pain sensitivity where observed (Gangadharan et 
49 
 
al., 2009). Experimental animals also presented gait alterations, showing functional 
locomotor impairment, probably ascribable both to myelination disorders and 
altered pain processing (Faroni et al., 2014).  
Another study, which analyzed GABA-B receptors localization in vitro and in vivo 
in Schwann cells, suggested that they may be particularly expressed in Schwann 
cells that are assuming the non-myelinating phenotype (Procacci et al., 2012). 
Indeed, immunofluorescence evaluations of coronal and longitudinal sections of rat 
sciatic nerves revealed that GABA-B receptors show some co-localization with 
glial fibrillary acidic protein (GFAP), a marker of non-myelinating Schwann cells, 
while there was almost no co-localization with the myelination marker MAG (that, 
as previously mentioned, is a key component of the adaxonal membrane (Procacci 
et al., 2012).   
Collectively, these lines of evidence suggest that GABA-A and GABA-B receptors 
may play a dualistic role in Schwann cells (Figure 9). Indeed, as just touched on, 
GABA-A activation through the neuroactive steroid allopregnanolone is able to 
positively modulate P0 an PMP22 expression (Melcangi et al., 1999, Magnaghi et 
al., 2001). Moreover, it is able to modulate the expression and responsiveness of 
GABA-B receptors (Magnaghi et al., 2006, 2010) and to stimulate Schwann cell 
proliferation (Perego et al., 2012). GABA-A activation also leads to an increase in 
the expression levels of GAD67 and, consistently, to increased GABA synthesis 
(Magnaghi et al., 2010). The trafficking of the EAAC1 transporter, which mediates 
the uptake of GABA precursor glutamate, is also regulated (Perego et al., 2012). 
On the other hand, GABA-B activation leads to a decrease in Schwann cell 
proliferation (Magnaghi et al., 2004) and induces their differentiation. Moreover, 
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GABA-B activation leads to a decrease in myelin proteins expression (Magnaghi et 
al., 2004).    
 
 
Figure 9 – Cross-interaction and dualistic effect of GABA-B receptors in Schwann cells. Adapted 
from Faroni and Magnaghi, 2011. 
 
Taken together, those findings suggest that the GABAergic system may play a role 
in Schwann cell differentiation, with GABA-A mainly involved in the regulation of 
the myelinating phenotype and GABA-B in the differentiation of non-myelinating 
Schwann cells (Faroni and Magnaghi 2011; Procacci et al., 2012; Faroni et al., 
2014). 
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PROTEIN KINASE C – TYPE ε 
 
GENERAL CONCEPTS 
 
Protein kinases (PKs) are a family of isoenzymes which are activated as second 
messengers, that act phosphorylating specific intracellular targets and therefore 
modulating different pathways. The most important sub-families of PKs are PKA 
and PKC. 
PKA is an isoenzyme that is activated following cAMP increased intracellular 
concentration, when a GPCR coupled with a Gs protein is activated. In general, the 
signal cascade following PKA activation leads to the modulation of specific genes’ 
expression. 
PKC is activated by phosphorylation and membrane translocation. The 
phosphorylation can be catalyzed by two different enzymes: diacylglycerol (DAG) 
and calmodulin. DAG is formed following the activation of GPCRs coupled with a 
Gq protein, which activates PLC that hydrolyzes phosphatidylinositol (PIP2) giving 
DAG and inositol trisphosphate (IP3). 
IP3 is able to induce Ca
++ release. Increased intracellular Ca++ levels are responsible 
for the other PKC activation mechanism. Indeed, calmodulin is activated after its 
binding with Ca++ and then phosphorylates PKC, activating it. Therefore, PKC can 
be activated through a G-protein mediated mechanism, but also by Ca++ 
intracellular fluctuations that can follow other biological events, such as activation 
of ion channels. 
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Ten PKC isoforms have been identified so far (Mellor and Parker, 1998) and they 
are classified into three groups, based on their activation mechanism (Nishizuka, 
1995). Conventional PKCs (α, βI, βII and γ) can be activated both by DAG and the 
Ca++-calmodulin complex. Novel PKC isoforms (δ, ε, η and θ) are activated only 
by DAG. Atypical PKCs (𝜉, 𝜆/𝜄) do not require any of the two enzymes to be 
activated, being in this way not under PLC control. Their activation mechanism 
requires the presence of phosphatidylserine. 
Several data suggest that, among other isoforms, PKCε plays an important role in 
the modulation of neuropathic pain. In the central nervous system, it resulted to be 
expressed mainly in the cerebral cortex, cerebellum and hippocampus. In small 
amounts, it is expressed also in peripheral non-nervous tissues (Saito et al., 1993; 
Chen et al., 2000).  
The first evidence pointing to PKCε role in pain modulation was its identification 
in the brain (Mochly-Rosen et al., 1987; Saito et al., 1998) and in primary peripheral 
neurons involved in nociception (Aley et al., 2000).  Moreover, PKCε potentiates 
afferent unmyelinated fibers signal (Dray et al., 1988; Rang et al, 1988), in 
particular C fibers, responsible for thermoception and nociception (Parada et al, 
2003; Cesare and McNaughton, 1996). Its activation increases sensory neurons 
sensitivity (Schepelmann et al., 1993), intensifying and prolonging painful stimuli. 
Consistently, PKCε inhibition blocks sensory neurons’ hyper stimulation (Burgess 
et al. 1989; McGuirk and Dolphin, 1992). In a model of inflammatory-derived 
hyperalgesia, temporary PKCε inhibition proved able to block the pathological 
state, suggesting its implication both in the early phase and in the chronicization of 
hyperalgesia (Parada et al, 2003).  
53 
 
From a mechanicistic point of view, PKCε exerts its pro-hyperalgesic effect 
phosphorylating both excitatory (such as voltage-operated Ca++ channels, VOCC, 
and transient receptor potential cation channel subfamily V member 1, TRPV1), 
and inhibitory (such as GABA-A and opioid μ receptors) channel receptors, 
activating the first and down-modulating the latter. TRPV1 is a non-specific ion 
channel activated by different ligands, such as anandamide (Zygmunt et al., 1999), 
Leukotriene B and other inflammatory mediators (Hwang et al., 2000) and 
capsaicin. It is believed to be an important mediator in inflammatory pain 
conditions, indeed it is expressed in nociceptive C fibers (Tominaga et al., 1998). 
Its physiological function is the transmission of painful stimuli due to high 
temperature, but in pathological conditions of hyperalgesia its opening can be 
triggered also at lower temperature. This phenomenon has been reported to be 
present after PKCε activation (Crandall et al.,2002). PKCε has also been shown to 
activate this receptor through phosphorylation (Olah et al., 2002) and to facilitate 
its membrane translocation in sensitive neurons (Morenilla-Palao 2004). 
Accordingly, PKCε inhibition is able to cause a lower TRPV1 response to capsaicin 
(Zhou et al., 2001). 
As mentioned before, PKCε mediated phosphorylation is also able to de-sensibilize 
opioid μ receptors (Zhang et al., 1990; Narita et al., 1997) and GABA-A receptors 
(McMahon and Koltzenburg, 1990; Si et al., 2004; Yamada and Akasu, 1996; Ma 
et al, 2006), leading to a hyper-excitation condition, typical of neuropathies.  
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CROSS-TALK WITH ALLOPREGNANOLONE AND GABA-A 
 
Several lines of evidence suggest that PKCε may be involved in a complex 
mechanism that involves GABA-A and allopregnanolone (Figure 10). Studies 
conducted with PKCε null mice (Hodge et al., 1999) revealed that these animals are 
hypersensitive to GABA-A receptor allosteric modulators’ behavioral effects 
(Hodge et al., 2002).  As previously stated, allopregnanolone is one of the most 
important allosteric modulators of the GABA-A receptor. Accordingly, similar 
results were obtained also in vitro, since the peptide-mediated blocking of PKCε 
translocation in cortical synaptosomes leads to increased sensitivity to 
allopregnanolone (Khasar et al., 1999, Hodge et al., 1999). 
As already mentioned, PKCε exerts its action though the phosphorylation of its 
substrates. Specifically, its action on the GABA-A receptor is mediated by the 
phosphorylation of the Serine 327 amino acidic residue of the γ2 subunit (Qi et al., 
2007). PKCε is also able to modulate GABA-A receptor trafficking, acting on the 
N-Ethylmaleimide-Sensitive Factor signaling pathway, being able in this way to 
decrease its plasma membrane localization (Chou et al., 2010). 
GABA-A de-sensitization seems to play a role in neuroactive steroids modulation 
of the receptor (Zhu and Vicini, 1997). Probably, the state of the receptors 
determines how responsive they are to neuroactive steroids. Furthermore, 
neuroactive steroids, and in particular allopregnanolone, can induce changes in the 
GABAergic neurotransmission through synaptic and extra synaptic receptor 
modulation. Recently, it has been demonstrated that neuroactive steroids may 
increase the surface expression of specific GABA-A receptors, mainly α4 
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containing ones, modulating GABAergic tonic inhibition in the hippocampus 
(Abramian et al., 2014). Other GABA-A allosteric modulator (such as 
benzodiazepines) have been reported to be able to influence their diffusion and 
clustering at synapses (Levi et al., 2015). On the other hand, neuroactive steroids 
potentiating effect can be decreased by the stimulation of PKC pathway, both in 
physiological and pathological conditions (Brussaard et al., 2000; Brussaard and 
Koksma, 2003; Maguire et al., 2005; Oberlander et al., 2012; Mtchedlishvili et al., 
2001; Kia et al., 2011). For example, neuroactive steroids modulatory effect is 
decreased in dentate granule cells from epileptic rats (Mtchedlishvili et al., 2001). 
At the same time, cell specific changes in GABA-A phosphorylation status may 
occur in several epilepsy models (Schwarzer et al., 1997; Fritschy et al., 1999; Peng 
et al., 2004) and in the temporal lobe of human epileptic individuals (Loup et al., 
2000; Ferando and Mody, 2012). A similar correlation can be observed when 
GABA-A receptor phosphorylation status changes after kindling; this changes, 
together with the modification of subunits composition, can contribute to the 
reduced response to neuroactive steroids (Kia et al., 2011; Carver et al., 2014). The 
diminished allopregnanolone sensitivity can increase the susceptibility to seizures, 
as it happens in catamenial epilepsy, where increased seizures probability correlates 
with progesterone decreased levels before the onset of menstruations (Reddy, 
2009). 
Some evidence supports the presence of a cross-talk between PKCε, neuroactive 
steroids and the GABA-A receptor in pain perception and transmission (Figure 10). 
Indeed, the synthesis of neuroactive steroids is up-regulated following neuropathic 
pain onset (Poisbeau et al., 2005), and also PKCε levels were observed to be 
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modulated in pathological pain condition (Parada et al., 2003). It has been proposed 
that allopregnanolone could participate to a compensatory mechanism that 
counteracts the sustained activation of spinal cord nociception in pathological 
conditions (Vergnano et al., 2007). 
PKCε presence and activity have been demonstrated also in the peripheral nervous 
system, and in particular in DRG neurons., where it may alter the permeability of 
N-type Ca++ channels and enhance nociception (Van Kolen et al., 2008). 
 
 
Figure 10 – cross-interaction between PKCε, the neuroactive steroid allopregnanolone and the 
GABA receptor. PKCε is a negative modulator of the GABA-A receptor and reduces its cell 
membrane expression. On the other hand, allopregnanolone is a positive modulator of the GABA-
A receptor and of its trafficking towards the cell membrane. Furthermore, it increases its synthesis. 
A direct interaction between PKCε and allopregnanolone, even if not well documented yet, is 
probable. Adapted from Puia et al., 2015.  
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NEUROACTIVE STEROIDS 
 
GENERAL CONCEPTS 
 
The term “neurosteroids” was firstly introduced by Baulieu and colleagues at the 
end of the ‘80s, to describe hormones synthesized by the nervous system, in order 
to differentiate them from hormones synthesized by classical steroidogenic tissues 
(Baulieu, 1997). The concept was furtherly developed in the following years, 
leading to the concept of “neuroactive steroids”, which includes properly defined 
neurosteroids, synthesized in the nervous system and acting on the nervous system, 
but also steroid hormones synthesized outside the nervous system but acting on it. 
Neurosteroids are synthesized in some cerebral area, including hypothalamus, 
hippocampus, cerebral cortex, cerebellum and peripheral nervous system (Mellon 
et al., 2001, Melcangi et al., 2001). For instance, Purkinje cells of the cerebellum 
and pyramidal neurons of the hippocampus are the major neuronal population 
producing neurosteroids in the brain (Ukena et al., 1999, Kimoto et al., 2001, Hojo 
et al., 2004). The first step in steroidogenesis is cholesterol conversion to 
pregnenolone, catalyzed by the mitochondrial cytochrome P450 cholesterol side-
chain cleavage enzyme (P450 SCC). This step requires cholesterol to be transferred 
from the outer mitochondrial membrane to the inner membrane, where P 450 SCC 
is located. The steroidogenic acute regulatory protein (StAR) and the translocator 
protein of 18 kDA (TSPO) are involved in this process, probably forming a complex 
(Stoffel-Wagner et al., 2003; Korneyev et al., 1993; Jefcoate, 2002; Papadopoulos 
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et al., 2006). It is interesting to note that TSPO is highly expressed in every 
steroidogenic tissue, including brain (Papadopoulos et al., 2006). 
Cholesterol is therefore converted to pregnenolone, which following different 
biosynthetic pathways, leads to the formation of neuroactive steroids (As shown in 
figure 11).  
 
  
Figure 11 – Neuroactive steroids synthesis. Cholesterol is converted to pregnenolone through the 
action of the P450 SCC enzyme, that is the substrate for the synthesis of other neuroactive steroids. 
Adapted from Carver and Reddy, 2013. 
 
Allopregnanolone and tetrahydro-deoxycorticosterone (THDOC), which are 
classified as pregnane steroids, are the most commonly studied endogenous 
neuroactive steroids (Reddy and Kulkarni, 2000; Belelli and Lambert, 2005). 
Pregnenolone, progesterone and deoxycorticosterone also exhibit neuroactive 
effects. Androstanes are another important class of neuroactive steroids. They 
include androstanol, androstanediol and testosterone (Reddy, 2004; Kaminski et al., 
2006; Reddy, 2008). 
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The first studies in the neuroactive steroids field mainly focused on the central and 
peripheral nervous system neurons. However, different studies pointed out to the 
important effects exerted by these neuroactive steroids on glia (Celotti et al., 1992, 
Melcangi et al., 2001). Glial cells, indeed, are able to synthesize steroid hormones, 
expressing the enzymatic machinery necessary for their synthesis, in particular 
CYP450 SCC, 17α- hydroxysteroid dehydrogenase (HSD) and 3β-HSD (Mellon et 
al., 2001). Furthermore, they also express the enzymes required for the conversion 
of steroid hormones to neuroactive steroids, in particular 5α-reductase and 3α-HSD. 
It is interesting to notice that these two enzymes resulted to be more expressed in 
glial cells than in neuronal ones. The presence of these enzymes has been 
characterized both at central (Steckelbroeck et al., 2001) and peripheral level 
(Melcangi et al., 1990, 1992, 1999; Celotti et al., 1992). 
 
MECHANISM OF ACTION 
 
It is possible to distinguish two different mechanisms of neuroactive steroids action:  
the classical genomic mechanism and the non-classical mechanism mediated by 
neuroactive steroids binding to different nervous receptors.  
The first mechanism is mediated by classical intracellular steroid hormone 
receptors. It involves the modulation of genic transcription and leads to slow but 
long-lasting effects. Different hormonal receptors have shown to be expressed by 
glial cells. The progesterone receptor (PR) has been shown to be present in rat 
Schwann cell culture and sciatic nerve (Jung-Testas et al., 1996; Jung-Testas and 
Baulieu, 1998; Thi et al., 1998; Magnaghi et al., 1999, 2001). The same study also 
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revealed the presence of the estrogen receptor (ER) in rat Schwann cell cultures 
(Jung-Testas and Baulieu, 1998). Also the androgen receptor (AR) was reported to 
be present in rat sciatic nerve (Jordan et al., 2002; Magnaghi et al., 1999).  
The non-classical mechanism, as already mentioned, involves neuroactive steroids 
binding with neurotransmitter receptors, such as the already cited GABA, N-
Methyl-d-aspartate (NMDA), 5-hydroxytryptamine type 3 (5-HT3) and opioid σ-
receptors (Lambert et al.,1996; Rupprecht et al., 2001; Monnet and Maurice, 2006; 
Sedlacek et al., 2008), leading to rapid actions mediated by the intracellular 
activation of second messengers.  
However, neuroactive steroid rapid actions may involve also the activation of novel 
putative membrane receptors for steroids (Hammes and Levin, 2007; Dressing et 
al., 2011; Levin, 2011; Faroni and Magnaghi 2011; Zhu et al., 2003a, b; Pang et al., 
2013).  
 
PROGESTERONE DERIVATIVES  
 
Among other neuroactive steroids, progesterone derivatives demonstrated to be 
very interesting for their ability to modulate the nervous system in different physio-
pathological conditions. 
As shown in Figure 11, progesterone derives from pregnenolone through a reaction 
catalyzed by the enzyme 3β-HSD. Progesterone can be subsequently converted to 
3α-dihydroprogesterone (DHP) by the action of the 5α-reductase. Both compounds 
are ligands of the classic PR. DHP can be further metabolized to 3α,5α-
tetrahydroprogesterone (THP), more commonly known as allopregnanolone, that 
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does not bind the PR, but is known to exert most of is action through the binding 
with the GABA-A receptor (Belelli and Lambert, 2005), already described above. 
This interaction was studied through patch clamp studies, revealing that it can be 
due both to positive allosteric modulation or direct activation of the GABA-A 
receptor, depending on concentration. In particular, at nanomolar concentration 
allopregnanolone acts as an allosteric modulator, while at micromolar concentration 
it is able to induce the Cl- channel opening even if GABA is not present (Callachan 
et al., 1987; Shu et al., 2004; Park-Chung et al., 1999; reviewed in Belelli and 
Lambert, 2005).   
Studies conducted using a chimeric receptor model allowed the identification of 
two different binding sites for neuroactive steroids on the GABA-A receptor, 
corresponding to two discrete groups of residues in the trans-membrane domains. 
The first binding site, defined as the “activation site”, is located at the interface 
between α and β subunits at the level of αThr236 and βTyr284 amino acidic 
residuals, and is responsible for the initiation of the direct activation of the receptor. 
The second binding site, instead, called “potentiation site”, is located in a cavity 
formed by α subunit transmembrane domains, between αGln241 and αAsn407, and 
mediates the potentiation of GABA or neuroactive steroids binding on the other 
site. The direct activation of the receptor requires allopregnanolone binding in both 
sites (Hosie et al., 2006). Both the activation and the potentiation sites are 
structurally highly conserved among different α and β sub-types, and δ subunit 
seems to be not involved in neuroactive steroids binding to the potentiation site, 
suggesting it may modulate neurosteroid potentiation by a mechanism other than 
by affecting their initial binding (Hosie et al., 2006, 2009).  
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Both synaptic and extra-synaptic receptors were reported to be modulated by 
allopregnanolone activity. Electrophysiological studies indicate that, in most brain 
regions, the neuroactive steroids activity at synaptic level produces a low effect on 
the rise time or amplitude of GABA-gated channel opening, prolonging instead the 
decay time of the event (Lambert et al., 2003). In particular, allopregnanolone, such 
as other positive modulators of the GABA-A receptor, exerts its action on the 
channel increasing the channel opening probability (Puia et al., 1990; Twyman and 
Macdonald, 1992; Zhu and Vicini, 1997), and prolonging the decay time of 
inhibitory post-synaptic currents (Harrison et al., 1987; Fáncsik et al., 2000). 
As previously mentioned, neuroactive steroids are importantly involved in the 
modulation of extra-synaptic GABA-A receptors.  Indeed, receptors containing the 
δ subunit instead of γ ones show a stronger GABA-A modulatory effects of 
neuroactive steroids (Belelli et al., 2002; Brown et al., 2002; Wohlfarth et al., 2002). 
This has been suggested to be true in particular in specific cerebral areas, such as 
the cerebellar granule cells (Stell at al., 2003). However, in other areas, such as 
thalamo-cortical neurons, extra-synaptic receptors are relatively insensitive also to 
high levels of allopregnanolone (Brown et al., 2009). Other factors, such as the 
phosphorylation state (as previously mentioned) and the local steroid metabolism 
may also contribute to this selectivity (Belelli et al., 2009). 
Furthermore, allopreganolone may be also retro-converted to DHP (Martini et al., 
2003) and interact with the classic PR (Rupprecht et al., 1993, Finn et al., 2006). 
DHP has less affinity than progesterone for the PR (Schumacher et al., 2007), 
however it has been reported to mediate some PR mediate effects, in particular on 
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GFAP in astrocytes and on P0 in Schwann cells (Melcangi et al., 1996, 2001; 
Martini et al., 2003, detailed below).   
 
PROGESTOGENS ACTION ON GLIAL CELLS 
 
Progestogens, and in particular allopregnanolone, have important effects on the 
glial cells of the central nervous system. In oligodendrocytes, allopregnanolone 
proved able to modulate the expression of MBP and the 2’-3’-cyclicnucleotide-3-
phospodiesterase (Verdi and Campagnoni, 1990; Jung Testas et al., 1996). For 
example, a study showed allopregnanolone and DHP ability to reverse age-related 
MBP down-regulation in old male rats (Ibanez et al., 2003). Progestogens ability to 
up-regulate MBP both through PR and GABA-A mediated mechanism was 
suggested also in organotypic cerebellum slice cultures of 7-days old mice and rats 
(Ghoumari et al., 2003). In these cells, neuroactive steroids and GABA signaling 
are also important regulators of the proliferation process and differentiation of 
oligodendrocyte progenitor cells. Indeed, the neuronal progenitor polysialylated-
neural cell adhesion molecule positive cells (PSA-NCAM+) express different 
GABA-A subunits, such as α1-5, β2-3 and γ2 (Nguyen et al., 2003, Gago et al., 
2004). There is evidence that allopregnanolone has a positive proliferative effect on 
these cells, since this effect is also exerted by GABA and blocked by bicuculline, 
suggesting that it is GABA- mediated (Gago et al., 2004). These data indicate that 
progestogens may have an important role in the maturation and development of 
oligodendrocytes (Ben-Ari, 2002, Gago et al., 2004), both through classic and non-
classic mechanisms.  
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Progestogens, in particular progesterone derivatives DHP and allopregnanolone, 
play an important role also in astrocytes cell physiology, in particular modulating 
GFAP expression, which has a role in the control of astrocytes shape and motility 
(Laping et al., 1994). In astrocytes cell cultures GFAP expression has been reported 
to be down-regulated by allopregnanolone and up-regulated by DHP (Melcangi et 
al., 1996). Allopregnanolone action may be mediated by the GABA-A receptor, 
whose subunit are widely expressed in astrocytes (Bovolin et al., 1992; Hosli et 
al.,1997; Israel et al., 2003).  
Progesterone and estrogens have been reported to exert anti-inflammatory effect in 
the central nervous system, mainly modulating microglial cells (Stone et al., 1997; 
Vegeto et al., 1999, 2001; Drew and Chavis, 2000; Bruce-Keller et al., 2001). The 
concentrations of allopregnanolone are remarkably high in the fetal brain and 
further rise in response to acute hypoxia, representing an endogenous protective 
mechanism in the developing brain (Hirst et al., 2006). Allopregnanolone is also 
reported to be a neuroprotective agent in different brain injury conditions, such as 
ischemic damage or oxygen glucose deprivation (Kelley et al., 2011, Ardeshiri et 
al., 2006). Even if these allopregnanolone effects may be linked to the regulation of 
anti-inflammatory cytokines and endogenous antioxidants, only little evidence 
supports a role for allopregnanolone in microglia modulation (Ghezzi et al., 2000, 
Djebaili et al., 2005).  
Nowadays, a consistent number of observations support the importance of 
neuroactive steroids, and in particular progestogens, in the regulation of Schwann 
cell patho-physiology. There is evidence they are able to modulate the expression 
of myelin proteins P0 and PMP22 in vivo in young and old male rats (Melcangi et 
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al., 1998, 1999, 2000, Magnaghi et al., 2001). In particular, P0 expression seems to 
be modulated mainly through a classic PR mediated mechanism, while PMP22 
expression resulted to be under allopregnanolone-GABA-A control (Magnaghi et 
al., 2001). Indeed, the allopregnanolone mediated up-regulation of PMP22 
expression was mimicked with GABA-agonist muscimol and blocked with its 
antagonist bicuculline (Magnaghi et al., 2001, 2006). However, also a classic PR 
mediated mechanism may be involved in the modulation of the latter, since 
mifepristone (RU38486), a classic PR antagonist, was able to counteract PMP22 
overexpression in a model of CMT-1A (Sereda et al., 2003).  Progestogens proved 
also able to exert positive effects in sciatic nerves after aging (Azcoitia et al., 2003), 
cryolesion (Koenig et al., 1995), transection (Melcangi et al., 2000) and crush injury 
(Roglio et al., 2008). 
As already mentioned, allopregnanolone is also involved in GABA receptors cross-
talk in Schwann cells. In particular, it has been proposed to exert a biphasic effect 
on GABA-B subunits expression, up-regulating them after short (4 hours) treatment 
and down-regulating their expression after 24 hours (Magnaghi et al., 2006). This 
effect was mimicked by muscimol and GABA, while the 24 hours effect was 
mimicked by progesterone and DHP (probably after conversion to 
allopregnanolone), further suggesting an important role for allopregnanolone in the 
modulation of Schwann cell physiology (Magnaghi et al., 2006; Magnaghi, 2007). 
Allopregnanolone has been hinted to have a role also in GABA synthesis in 
Schwann cells, being able to modulate GAD 67 expression (Magnaghi et al., 2010). 
Moreover, it regulates the uptake of GABA biological precursor, glutamate, 
through membrane translocation of the EAAC1 glutamate transporter, in a process 
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that involves PKC activation (Perego et al., 2012). Through the regulation of the 
trafficking of this transporter, allopregnanolone has also been shown to induce 
Schwan cells proliferation in vitro (Perego et al., 2012). 
 
NOVEL SIGNALING PATHWAYS 
 
Aside neurotransmitter receptors, several other receptors have a role in the 
modulation of non-classical action of neuroactive steroids, in particular membrane 
progesterone receptors (mPRs: mPRα, mPRβ, mPRγ, mPRδ and mPRε), the 
progesterone receptor membrane component 1 (PGRMC1) and the pregnane X-
receptor (PXR, Figure 12).  
PXR is a promiscuous nuclear receptor, activated by different compounds, 
including steroids, whose expression has been detected in different parts of the brain 
and spinal cord (Lamba et al., 2004; Ma et al., 2008, Mellon et al., 2008). It is 
known to be a key modulator of xenobiotic action (Kliewer et al., 2002) 
Allopregnanolone has been reported to activate PXR both in vivo and in vitro and 
to induce PXR target genes (Lamba et al., 2004; Langmade et al., 2006). 
Progesterone, otherwise, has low affinity for this receptor (Cooke et al., 2013). PXR 
seems to mediate some neuroprotective actions of allopregnanolone, in particular 
following traumatic brain injury (Cooke et al., 2013) and in a murine model of 
Niemann-Pick C disease (Langmade et al., 2006). 
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Figure 12 – Schematic representation of known target receptors of progestogen neuroactive steroids. 
Progesterone exerts its action through PGRMC1, mPRs and the classic PR. DHP action has been 
characterized only through the binding with PR. The most studied target for allopregnanolone, which 
does not bind PR, is the GABA-A receptor; however recent evidence suggests that also mPRs and 
PXR are mediators of allopregnanolone pharmacological activity. Adapted from Cooke et al., 2013.   
 
PGRMC1 
 
PGRMC1 is a member of a group of molecules which are characterized by the 
presence of highly conserved cytochrome b5/heme steroid binding domain, that 
include also include PGRMC2, neudesin and neuferricin (Kimura et al., 2012). 
PGRMC1 is the only member of this family who has been reported to bind 
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progesterone (Meyer et al., 1996; Peluso et al., 2008, 2009). It was originally cloned 
in 1996 from porcine liver (Falkenstein et al., 1996) and is widely expressed in 
brain and up-regulated after brain injury, both in neurons and astrocytes (Meffre et 
al., 2005; Guennoun et al., 2008; Intlekofer and Petersen, 2011; Petersen et al., 
2013). mRNA expression data support an important expression of PGRMC1 in 
discrete neuroendocrine nuclei and in hippocampal, cortical and cerebellar regions 
(Intlekofer and Petersen, 2011). It is also expressed in regions involved in the 
production and osmoregulation of the cerebrospinal fluid, suggesting it may play a 
role in progesterone beneficial effects on the blood-brain barrier after traumatic 
brain injury (Meffre et al., 2005).  
The mechanism by which PGRMC1 mediates neuroprotective progesterone actions 
is not clear, but it may involve the up-regulation of BDNF, which is reported to 
promote neuronal survival (Gonzalez et al., 2005). Moreover, it is reported that in 
glial cell lines and primary astrocytes PGRMC1 activation is able to induce BDNF 
increased release through a Erk5 mediated mechanism (Su et al., 2012). 
PGRMC1 expression has been found also in spinal cord neurons, in particular in 
the dorsal horn and ependymal cells lining in the central canal (Guennoun et al., 
2015). It was reported to be up-regulated in dorsal horn after injury, pointing out to 
a possible protective role for PGRMC1 also at this level (Labombarda et al., 2003) 
Even if progesterone binds PGRMC1 in membrane fractions (Falkenstein et al., 
1999), there is no consensus about the effective ability of PGRMC1 to bind 
progesterone and originate intracellular responses in vitro or in vivo (Cahill, 2007; 
Price, 2013). PGRMC1 does not appear to function as a traditional receptor, 
requiring a binding partner known as serpine mRNA binding protein 1 (Serbp1, 
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Peluso, 2006). It was also suggested that PGRMC1 may represent the σ-2 receptor 
binding site (Xu et al., 2011). Allopregnanolone binding with PGRMC1 has not 
been analyzed yet (Cooke et al., 2013). 
Recent data show that PGRMC1 can function as an adaptor protein, mediating 
mPRα translocation to the cell membrane, and that PGRMC1 actions may be 
therefore mediated by the formation of membrane progesterone receptor complex 
formed by PGRMC1 and mPRα, with the latter being responsible for progesterone 
binding and intracellular signaling (Thomas et al., 2014).  
 
mPRs 
 
mPRs are a group of progesterone binding receptors localized on the cell 
membrane, belonging to the progestin and adipoQ receptor (PAQR) family 
(Thomas et al., 2007, Tang et al., 2005). The first member of this family, mPRα 
(also known as PAQR7), was originally identified in spotted seatrout ovaries and 
was demonstrated to be a membrane steroid receptor, with a saturable, displaceable, 
single binding site specific for progestogens (Zhu et al., 2003b). Shortly after the 
first detection of this first receptor, it became clear that mPRα was member of a 
receptor family, including mPRβ or PAQR8 and mPRγ or PAQR5, and that 
homologous to these genes were present in several vertebrates, including humans 
(Zhu et al., 2003a). Subsequently two other members of this family, previously 
characterized only in yeast recombinant expression systems (Smith et al., 2008) 
were identified: mPRδ or PAQR6 and mPRε or PAQR9 (Pang et al., 2013). 
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They are metabotropic receptors with seven trans-membrane domains, coupled to 
G proteins. In particular, mPRα, β and γ seem to be coupled to an inhibitory Gi/0 
protein (Zhu et al., 2003a, b; Thomas et al., 2007), while mPRδ and ε are coupled 
with stimulatory Gs proteins (Pang et al., 2013). 
Studies conducted on the human mPRα have shown clearly that it has a distinct 
binding profile compared to PR, and specific mPR ligands (19α-
methylprogesterone or Org OD 13-0 and 10-ethenyl-19-norprogesterone or Org OD 
02-0) suitable for physiological analyses have been identified (Kelder et al., 2010).  
In the last years, different studies evaluated mPRs expression in different areas of 
the central nervous system (Zhu et al., 2003b; Labombarda et al., 2010; Intlekofer 
and Petrsen, 2011; Zuloaga et al., 2012; Pang et al., 2013, Meffre et al., 2013). A 
first study evaluated by in situ hybridization the mRNA expression of mPRα and β 
(plus PGRMC1, 2 and Serbp1) in female rats. The results of this study suggest that 
mPRα and β expression is low and homogeneous in the hypothalamus, being higher 
in thalamic and cortical brain regions, suggesting a possible role for them in the 
mediation of progestogen actions in cognitive and sensory functions (Intlekofer and 
Petrsen, 2011). However, a later study, performed using different techniques such 
as saturation binding, quantitative Real Time polymerase chain reaction (qRT-
PCR), Western Blot and immunohistochemistry, has shown specific mPR 
progesterone binding in rat cortex, hypothalamus and pre-optic area obtained from 
female rat brain. qRT-PCR analysis has shown that mPRβ is more expressed than 
mPRα in all those areas, and subsequent immunohistochemistry analysis of mPRβ 
localization suggested that it particularly expressed in in select nuclei of the 
hypothalamus (paraventricular nucleus, ventromedial hypothalamus, and arcuate 
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nucleus), forebrain (medial septum and horizontal diagonal band), and midbrain 
(oculomotor and red nuclei) and throughout many areas of the cortex and thalamus 
(Zuloaga et al., 2012). Another study, that analyzed mPRα expression by in situ 
hybridization and immunofluorescence in mouse and rat brain, found that it is 
particularly expressed in olfactory bulb, striatum, cortex, thalamus, hypothalamus, 
septum, hippocampus and cerebellum, with a pattern similar to 3β-HSD, the 
enzyme that converts pregnenolone to progesterone. Interestingly, its expression 
resulted to be specific to neurons in physiological conditions, being absent in 
oligodendrocytes and astrocytes (Meffre et al., 2013). Lastly, all five mPR isoforms 
expression was evaluated in human brain by qRT-PCR (Table 1), shown that mPRδ 
is the most abundant mPR isoform in the human brain, in particular in corpus 
callosum and hypothalamus, being also higher than other isoforms in neocortex 
lobes, the limbic system (amygdala, hippocampus, and nucleus accumbens), 
thalamus, and in brain regions important for memory and movement (caudate, 
putamen), reward (substantia nigra), and autonomic functions (medulla and pons). 
mPRβ expression was high in similar regions compared to mPRδ, such as the corpus 
callosum, hippocampus, hypothalamus, substantia nigra and cerebellum. mPRα 
expression was lower in many regions compared to mPRδ, mPRβ and mPRε, with 
highest levels being detected in temporal lobe and medulla oblongata. mPRγ levels 
were lower than the other mPRs, with highest relative levels being expressed in 
choroid plexus and pons. mPRε highest relative levels were observed in the 
pituitary gland and hypothalamus, while relatively high expression levels were 
observed also in areas where mPRδ was highly expressed, such as the limbic 
system, the caudate, the nucleus accumbens, the pons and the olfactory bulb. 
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Interestingly, mPRδ, that seems to be a neuron-specific form, resulted to be the 
mPR isoform with the highest affinity for allopregnanolone, that is able to bind all 
mPR subtypes, even if with lesser affinity than progesterone (ranging from 4.00% 
of progesterone affinity for mPRε to 33.64 % for mPRδ, Pang et al., 2013). 
mPRs expression was evaluated also in the spinal cord. mPRα, β and γ were 
identified by RT-PCR in mice spinal cord, while only α and β were detected also 
following in situ hybridization. This discrepancy may be due to low mPRγ levels. 
mPRα expression resulted to be constitutive and widespread, with no significant 
differences between males and females, and not being altered by PR knockout. In 
situ hybridization analysis showed its presence in ventral horn motor neurons and 
dorsal horn interneurons. Specific immunostaining in both gray and white matter 
revealed that almost all astrocytes and oligodendrocytes, as well as an important 
fraction of NG+ precursor cells expressed mPRα. The same analysis showed that 
mPRβ, instead, presents a much more restricted distribution, being absent in the 
dorsal horn and glial cells (Labombarda et al., 2010). qRT-PCR studies in human 
spinal cord revealed that the most expressed isoforms are mPRδ and mPRβ, 
followed by mPRγ, mPRα and mPRε (Pang et al., 2013).  
Several lines of evidence suggest that mPRs may be involved in the modulation of 
several progestogen neuroprotective actions in the nervous system. For example, a 
study conducted using the GT1-7 neuronal cell line model, which express mPRα 
and β (Sleiter et al., 2009) and very low level of mPRδ, has shown that both 
progesterone and allopregnanolone at 20 and 100 nM concentration were able to 
significantly reduce apoptosis in a serum-starvation cell death induced experiment 
(Thomas and Pang., 2012). A similar effect was observed in mPRδ transfected cells 
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and in hippocampal cell line, suggesting that mPRδ could contribute to this anti-
apoptotic effect (Pang et al., 2013). Another study revealed that, even if mPRα is 
not expressed in rat brain by central glial cells in physiological conditions, its 
expression is induced after traumatic brain injury in oligodendrocytes, astrocytes 
and microglia, both in the lesion core and peri-lesioned area, suggesting it may have 
a role in glia-mediated neuroprotective action of progesterone (Meffre et al., 2013). 
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Aims 
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Nowadays, therapeutic approaches to peripheral neuropathies are, in the majority 
of cases, still aimed to symptomatic relief, with no specific drugs able to lead to full 
nerve regeneration. This is due to the fact that in most of the cases, the etiology and 
cellular mechanism of this pathologies are unknown. Therefore, the identification 
of new specific drugs or alternative approaches, relying on the deep knowledge of 
the mechanisms regulating the peripheral nervous system, represents a strong and 
actual medical need. 
Among the many different mediators which have been reported to have a role in the 
development and, possibly, on the cure of peripheral neuropathies, the laboratory 
in which I carried out my PhD studies has always focused on the role of the 
GABAergic system and neuroactive steroids.  
Therefore, the aim of my PhD project was to deepen the study on the GABAergic 
system and neuroactive steroids, in particular progestogens, in order to unravel their 
role in peripheral neuropathies and neuropathic pain. Moreover, our studies were 
aimed at the identification of new specific drugs for the treatment of neuropathies. 
The studies conducted can be divided into four research lines: 
 Study of the role of the GABAergic system, in particular through the 
evaluation of the effects of specific GABA-B ligands, on nerve regeneration 
in an experimental model of nerve injury. 
 Study of the cross-correlations between the GABA-A and GABA-B 
receptors in a conditional knockout mice model. 
 Study of the interaction among allopregnanolone, GABA-A receptor and 
PKCε in Schwann cell and primary sensory neuronal cultures. 
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 Characterization of the expression of a novel class of membrane 
progesterone receptors (mPRs and PGRMC1) in Schwann cells and 
evaluation of their potential role in the modulation of their physiology. 
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Materials and Methods 
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ANIMALS  
 
For the experiments described in the first part of chapter 1 and in chapter 2 of the 
results section, male Sprague-Dawley rats were used. They were purchased from 
an authorized breeder (Charles River, Calco, Italy) at the age of 3-4 months old and 
used for experimental procedures shortly after.  
For the experiments described in the second part of chapter 1, GABA-B1fl/fl mice 
(Haller et al., 2004) were crossed with P0-CRE deleter mice (Feltri et al., 1999) to 
obtain P0-CRE_GABA-B1fl/wt mice, which were then back-crossed with GABA-
B1fl/fl mice. The resulting P0-CRE_GABA-B1fl/fl mice, with specific deletion of 
GABA-B1 in Schwann cells, were chosen as experimental group, and were 
compared with GABA-B1fl/fl mice chosen as control (Faroni et al., 2014). 
Experiments were conducted on 3 months old animals.  
All animals were bred in the animal facility of the Department of Pharmacological 
and Biomolecular Sciences of the University of Milan. They had access to water 
and food ad libitum and were maintained in a 12 hours of light/12 hours of dark 
daily cycle. All the experiments were performed according to the guidelines of the 
Animal Research Committee of our Institution and in compliance with the policy 
on the use of animals approved by the European Community Council Directive 
(2010/63/EC) and the Italian law on the use of animals for scientific studies (D.Lgs. 
26/2014). The study was approved by the Animal Care and Use Committee of the 
University of Milan. 
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GENOTYPING 
 
For the experiments described in the second part of chapter 1, animals genotype 
was determined by PCR analysis on genomic DNA, extracted from tails, sciatic 
nerves and liver using microLYSIS®–Plus (Microzone Limited, Haywards Heath, 
UK) following manufacturer’s protocol. Used primers are reported in Table 1. PCR 
reaction with CRE-1 and CRE-2 primers on mice tails extracts allowed to determine 
which mice expressed the CRE recombinase; reactions with P5 and P6 on mice tails 
extracts allowed to determine which mice presented inserted sequences in the 
GABA-B1 gene; lastly, post-mortem reactions with P7 and P8 on sciatic nerve and 
liver extracts allowed to verify the GABA-B1 exon VII and VIII specific deletion 
in Schwann cells (Faroni et al., 2014).  PCR was performed in a standard reaction 
mix under the following conditions (30 cycles): 94°C for 30 s; 56°C for 1 min; 72°C 
for 1 min. A final extension step at 72°C for 10 min was performed. The amplified 
products were analyzed on 1.5% agarose gels. 
 
CELL CULTURES 
 
For the experiments described in chapter 1 and 2, Schwann cells and DRG neurons 
primary cultures were used. 
Schwann cell cultures were obtained from sciatic nerves of rats and mice. Non-
nervous tissue was removed, then the nerve was cut in fragments (2–3 mm each), 
and placed in a 35 mm petri dish with the culture medium: DMEM (Dulbecco’s 
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modified Eagle’s medium) plus 10% fetal bovine serum (FBS; Life Technologies 
Italy, Monza, Italy) and 2 μM forskolin (Sigma-Aldrich Italy, Milan, Italy).  
 
Primer name 5'-3' sequence 
CRE-1 CCACCACCTCTCCATTGCAC 
CRE-2 GCTGGCCCAAATGTTCGTGG 
P5 TGGGGTGTGTCCTACATGCAGCGGACGG 
P6 GCTCTTCACCTTTCAACCCAGCCTCAGGCAGGC 
P7 ATCTCTTCCTTGGGCT GGGTCTTTGCTTCGCTCG 
P8 GGGTTATTTGAATATGATCGGAATTCCTCGACT 
 
Table 1 – Primer sequences used for genotyping. 
 
For mice cultures, 2% insulin growth factor (Sigma-Aldrich Italy) was added. After 
two weeks, the sciatic nerves were digested with 0.0625% (w/v) collagenase Type 
IV (Worthington Biochemical, Lakewood, NJ) and dispase (0.5 mg/mL; Life 
Technologies Italy), then mechanically dissociated, filtered through 100 μm filters 
(BD Biosciences, San José, CA) and centrifuged 5 min at 1100 rpm. Pellets were 
re-suspended in the culture medium, and then the cell suspension was seeded on 60 
mm petri dishes coated with Poly-L-lysine and laminin (Sigma-Aldrich Italy) and 
grown in presence of 2 μM forskolin at 37°C, 5% CO2, and 95% humidity. 
DRG neuronal cultures were obtained from the spinal cord of mice and rats. The 
DRG were dissociated by 40 minutes incubation in Ham’s F12 medium (Life 
Technologies Italy) containing 0.125% (w/v) collagenase Type IV (Worthington 
Biochemical), then treated for 30 min with 0.25% (w/v) trypsin (Worthington 
Biochemical). The dissociated DRG neurons were filtered through a 100 μm 
membrane (BD Biosciences) and centrifuged 5 min at 500 rpm. Cells were then re-
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suspended in Ham’s F12 and purified on a gradient of 15% (w/v) bovine serum 
albumin (BSA; Sigma-Aldrich Italy). Dissociated neurons were re-suspended in 
modified Bottenstein and Sato’s medium (BSM; F12 medium plus 100 μM 
putrescine, 30 nM sodium selenite, 20 nM progesterone, 1 mg/mL BSA, 0.1 mg/mL 
transferrin, and 10 pM insulin, all Sigma-Aldrich Italy). A cell suspension of DRG 
neurons was seeded on 35 mm petri dishes coated with poly-L-lysine and laminin 
(Sigma-Aldrich Italy). After 2 h, NGF 50 ng/mL was added and the cells grown at 
37°C, 5% CO2, and 95% humidity. 
For the experiments described in chapter 3, a Schwann cell line model was used. 
S42 (ATCC® CRL2942™) Schwann cells (ATCC, Manassas, VA) were thawed 
and re-suspended in the culture medium: DMEM (Sigma-Aldrich, St. Louis, MO) 
plus 10% FBS (Thermo Fisher Scientific, Waltham, MA) and seeded in T75 cell 
culture flasks. Before experimental procedures, cells where differentiated for 1-2 
days by adding 10 μM forskolin (Sigma-Aldrich) to the culture medium.  
 
SURGICAL PROCEDURE 
 
For the experiments described in the first part of chapter 1, rats were anesthetized 
by an intraperitoneal injection of a mixed solution of ketamine (80mg/Kg) and 
xylazine (5mg/Kg). After that, animals underwent surgical procedure following the 
procedure of the partial sciatic ligation (PSL) model, as previously described 
(Seltzer et al., 1990). An incision was made through skin and muscle of the right 
hind limb in order to expose the nerve. For every group, except the sham operated 
one, the nerve was ligated with a node made using a suture (Vicryl 3-0 2) which 
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crossed the nerve at half or 1/3 of its diameter, 1 cm proximally to the forking of 
the sciatic nerve into the peroneal and tibial branches. 
 
 
IN VIVO PHARMACOLOGICAL TREATMENTS 
 
In each experiment described in the first part of chapter 1, 4 rats were used as sham 
operated animals (control group), while 16 rats underwent PSL. PSL rats were 
divided into 4 experimental groups for treatments: (1) PSL + vehicle (saline 
solution); (2) PSL + baclofen (Bac in graphics, 10mg/kg); (3) PSL + CGP56433 
(CGP in graphics, 3mg/kg); (4) PSL + baclofen + CGP56433. The pharmacological 
treatments started the day of PSL surgery (day 0) and lasted 7 days, consisting in 
drugs intraperitoneal injection every 12 hours. All drugs were kindly provided by 
Dr. Klemens Kaupmann, Novartis Pharma AG, Basel, Switzerland. 
 
IN VITRO PHARMACOLOGICAL TREATMENTS 
 
For the experiments described in chapter 2, cells were incubated overnight in 
serum-free medium (DMEM only for Schwann cells, F12 only for DRG neurons), 
and were then treated with allopregnanolone (Sigma-Aldrich Italy) for 24 hours at 
a final concentration of 1 μM, diluted in the same serum-free medium. For the 
conditioned medium experiments, Schwann cell primary cultures where incubated 
overnight in serum-free medium and then treated with allopregnanolone for 24 
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hours. Their culture medium was therefore aspirated and transferred onto DRG 
neurons, that were previously incubated overnight in serum-free medium.  
For the experiments described in chapter 3, S42 Schwann cells were incubated 
overnight in serum-free medium and then treated with the following drugs: 10-
ethenyl-19-norprogesterone (O2, Organon, Oss, The Netherlands), progesterone 
(P4 in graphics, Steraloids, Newpot, RI) and promegestone (R5020, GE Healthcare, 
Piscataway, NJ), all at the final concentration of 20 nM.  
 
WALKING TEST 
 
For the experiments described in chapter 1, the walking footprint test was 
performed on all rats of each experimental group, at the end of pharmacological 
treatments. Rats with their hind feet stained with black ink were placed on a 100 
cm long gangway, which yielded at least 10 footprints per rat. Rats did not undergo 
any training before the test. Footprints were acquired and analyzed with the 
Footprint 1.22 software (Klapdor et al., 1997). The parameters analyzed were the 
area touched by a single step (in cm2), the toe 1–5 and 2–4 spreads (in cm), the 
length of the foot step (in cm), the stride width and the stride length (in cm). Data 
of each parameter are mean of 8–10 footprints of each animal. 
 
RNASE PROTECTION ASSAY (RPA) 
 
For the experiments described in chapter 1, total RNA was extracted from sciatic 
nerves by phenol-chloroform extraction and quantified using the Nanodrop 
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(Thermo-Fisher Scientific). 5 𝜇g of each sample were dissolved in 20 𝜇L of 
hybridization solution containing [32P]-labeled cRNA probes, 250,000 counts per 
minute (CPM) for P0 and PMP22 and 50,000 CPM for 18S, and incubated at 45°C 
overnight. The following day, the samples were incubated 30min at 30°C with 
200μL of digestion buffer containing 1 μg/μL RNase A and 20 U/μL RNase T1 
(Sigma-Aldrich, Milan, Italy) then treated for 15 min at 37°C with 10μg of 
proteinase K and sodium dodecyl sulfate (SDS) 20%. After phenol-chloroform 
extraction, the samples were separated on a 5% polyacrylamide gel, under 
denaturing conditions (7 M urea). The protected fragments were visualized by 
autoradiography. The levels of P0 and PMP22 and 18S rRNA were calculated by 
measuring the peak densitometric area with Image J software (NIH, Bethesda, MD) 
and data were normalized on 18S rRNA. In order to ensure that the auto 
radiographic bands were in the linear range of intensity, different exposure times 
were used. The mean values of the controls from different experiments were within 
10% of each other. 
 
qRT-PCR AND RETRO TRANSCRIPTION-PCR (RT-PCR) 
 
For all the qRT-PCR experiments described, total RNA was extracted from samples 
using TRI reagent (Sigma-Aldrich), following manufacturer’s instructions, and 
quantified using the Nanodrop. Samples were treated with the TURBO DNA-freeTM 
kit (Thermo-Fisher Scientific), in order to remove any DNA residual. RNA was 
retro-transcribed to cDNA using iScript™ Reverse Transcription Supermix for RT-
qPCR (Bio-Rad, Hercules, CA). 10 ng of cDNA for each sample were then used 
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for Real Time PCR. Every sample was run in triplicate. For the experiments 
described in chapter 1 and 2, Real Time PCR was performed using a CFX96 touch 
thermal cycler (Bio-Rad); for the ones described in chapter 3, instead, it was 
performed with a Mastercycler® RealPlex 2 (Eppendorf North America, 
Hauppauge, NY). In both cases, SsoAdvanced Universal SYBR Green Supermix 
(Bio-Rad) was used. Data analysis was performed according to the Pfaffl method 
(Pfaffl, 2001), and results are expressed as relative expression normalized on the 
geometric mean of a set of housekeeper genes (Table 2). Primers for qRT-PCR were 
designed using the PrimerBlast software (NIH, Ye et al., 2012), with the exception 
of the ones for PKCε, who were obtained from literature (Li et al., 2006, Table 2). 
For the RT-PCR experiments described in chapter 3, total RNA extracted from cells 
as described above for qRT-PCR was reverse transcribed into cDNA using 
SuperScript III (Thermo-Fisher Scientific), following mafucaturer’s protocol. The 
obtained cDNA was used as a template for PCR, which was performed in a standard 
reaction mix. Used primers are reported in Table 2. The cycling profile was the 
following: 94°C for 30 sec, 60°C for 30 sec, and 72°C for 1 min for 30 cycles, 
followed by a 72°C, 10 min extension step. The amplified products were analyzed 
on 1.5% agarose gels.  
Primer name (Accession 
number) 5'-3' sequence 
TARGET GENES 
PKCε-F (NM017171.1) CCCCTTGTGACCAGGAACTA 
PKCε-R AGCTGGCCATCAGTAGACGA 
RAα2-F (NM008066.3) AGACCAGGACTGGGAGACAGTA 
RAα2-R AGACAGGGCCAAAACTGGTCA 
RAα3-F (NM008067.4) GCTTAGCCTCCAACTTGTTTCTCC 
RAα3-R GAAGAGACCTGTGAGATCGAGTGT 
RAα4-F (NM010251.2) TCCTGGATTTGGGGGTCCTGTTA 
RAα4-R TCAACATCAGAAACGGGCCCAA 
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RAα5-F (NM176942.4) CCAGTCACTTTGGCTTTTCGCA 
RAα5-R AGGCCGCAGTCTGTTGTCAT 
RAβ1-F (NM008069.4) TTGGGGCTTCTCTCTTTTCCCG 
RAβ1-R TGCTGGGTTCATTGGAGCTGT 
RAβ2-F (NM008070.3) TGCTGGGTTCATTGGAGCTGT 
RAβ2-R CGCACGGCGTACCAAAACAT 
RAβ3-F (NM008071.3) TGTCACTGGCGTGGAAAGGA 
RAβ3-R ATAGGCACCTGTGGCGAAGA 
RAγ2-F (NM177408.6) CATGGAGCATTGGAAGCTCAGTC 
RAγ2-R TGTGAAGCCTGGGTAGAGCGAT 
Raδ-F (NM008072.2) TGCCCACTTCAATGCCGACT 
Raδ-R CATCCATCTCTGCCCTTGGCTT 
mPRα-F 
(NM001034081.1) GTGCACCGCATCATAGTGTC 
mPRα-R TGATAGTCCAGCGTCACAGC 
mPRβ-F 
(NM001014099.1) CTGCAGCCTCTTGGCCCACC 
mPRβ-R CAGCCGCCGGCAGGAAGAAA 
mPRγ-F 
(NM001014092.1) TACATTGGCCACAGTCACCAGC 
mPRγ-R AGCCAGCACCACATCAACGA 
mPRδ-F 
(NM001191077.1) GCAAACAGGTCAACGTGGAGGTA 
mPRδ-R ACCAAGTGGGCAGGAAGTGA 
mPRε-F (NM198414.2) TGGGCACAAAGACGCAAACC 
mPRε-R TGACACTCACAGGCCTTCACA 
PGRMC1-F 
(NM021766.1) TGACCAAAGGCCGCAAGTTCT 
PGRMC1-R CCACGTGATGGTACTTGAAGGTGA 
P0-F (NM017027.2) CCTGCTCTTCTCTTCTTTGGTGCT 
P0-R GGTTGACCCTTGGCATAGTGGA 
MAG-F (NM017190.4) GCCAGACCATCCAACCTTCTGT 
MAG-R AAGTCGAAACGGCAGGGGAT 
GFAP-F (NM017009.2) ACGTTAAGCTAGCCCTGGACAT 
GFAP-R ACTCCTTAATGACCTCGCCATCC 
PMP22-F (NM017037.1) CCCTGGCTCTCGATTGCAAAGAA 
PMP22-R CTGAAGCCATTCGCTCACAGATG 
HOUSEKEEPER GENES 
α-tubulin-F (m+r) 
(NM_022298.1; 
NM011653.2) TCGCGCTGTAAGAAGCAACACC 
α-tubulin-R (r) GGAGATACACTCACGCATGGTTGC 
α-tubulin-R (m) ATGGAGATGCACTCACGCATGG 
β-Actin-F (r) 
(NM031144.3) ACAGCTGAGAGGGAAATCGTGC 
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β-Actin-R (r) CCACAGGATTCCATACCCAGGAAG 
β2-microglobulin-F (m) 
(NM009735.3) CCCTGGTCTTTCTGGTGCTTGT 
β2-microglobulin-R (m) ATGTTCGGCTTCCCATTCTCCG 
β2-microglobulin-F (r) 
(NM012512.2) GCTTGCCATTCAGAAAACTCCCC 
β2-microglobulin-R (r) TGACGGTTTTGGGCTCCTTCA 
Table 2 – Primer sequences used for qRT-PCR and RT-PCR (F: forward; R: reverse; RA: GABA-
A receptor subunit; m: mouse; r: rat). Accession numbers are reported alongside forward primers. 
PROTEIN EXTRACTION AND PLASMA MEMBRANE PREPARATION 
 
For some the experiments described in chapter 3, cells were collected in ice-cold 
HAED buffer (25 mM HEPES, 10 mM NaCl, 1 mM dithioerythritol, and 1 mM 
EDTA) at pH 7.6, containing 1% protease inhibitor cocktail (Pierce, Rockford, IL). 
Cells were then homogenized using a sonicator, and the homogenate was 
centrifuged for 7 min at 1000 x g. The supernatant was collected as protein sample. 
For some experiments, this step was followed by centrifugation of the supernatant 
at 20,000 x g for 20 min to pellet plasma membranes, that were then re-suspended 
in HAED buffer. For some studies, the plasma membrane was furtherly purified by 
centrifuging it with a sucrose pad (1.2 M sucrose) at 6,900 x g for 45 min.  In this 
case, the membrane layer on the sucrose pad was collected and centrifuged again at 
20,000 x g for 20 minutes.  
 
WESTERN BLOT 
 
For the experiments described in chapter 2 and 3, protein samples were heated for 
20 minutes at 55°C or for 1 min at 100°C to denaturate their secondary structure, 
then 10-15 μg were loaded onto a SDS-PAGE gel and run at 200 V for 40 min in 
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running buffer. Gels were then electro-blotted to Hybond nitrocellulose membrane 
(GE Healthcare). Membranes were blocked with 5% not-fat dry milk (Bio-Rad) in 
PBS before incubation with the primary antibody diluted in the blocking solution. 
Primary antibodies used were rabbit anti PKCε (1: 200, Abcam, Cambridge, UK), 
rabbit anti-mPRα (1: 1,000, Sigma-Genosys, Woodlands, TX), rabbit anti-mPRβ 
(1: 1,000, Sigma-Genosys), rabbit anti-mPRγ (1: 1,000, Sigma-Genosys), rabbit 
anti-mPRδ (1:200, Sigma-Aldrich), rabbit anti-mPRε (1:1,000, Sigma-Genosys), 
goat anti-PGRMC1 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), mouse 
anti-MAG (1: 100, EMD Millipore, Billerica, MA) and mouse anti-Actin (1:1,000, 
Abcam) as loading control. In some cases, membranes were incubated with 
appropriated HRP-conjugated secondary antibodies (diluted 1:8,000-1:10,000, 
Millipore, Temecula, CA), and immune-complexes were revealed by enhanced 
chemiluminescence (ECL; Thermo-Fisher Scientific) and detected with 
photographic film (Nikon, Tokyo, Japan) or the ChemiDoc™ XRS+ system (Bio-
Rad). In other cases, specific secondary antibodies compatible with the Odyssey® 
CLx system (LI-COR, Lincoln, NE) were used, and their IR emission was detected.   
 
MORPHOMETRIC ANALYSIS 
 
For the experiments described in chapter 1, rats were perfused transcardially, under 
deep anesthesia, with 2% PFA and 2% glutaraldehyde solution in 0.1 M sodium 
cacodylate buffer (all Sigma-Aldrich Italy) at pH 7.3. After fixation, sciatic nerves 
were removed and immersed in the same fixative solution overnight at 4°C. The 
specimens were then post-fixed in 2% OsO4 (Sigma-Aldrich Italy), dehydrated, and 
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embedded in Epon-Araldite (Sigma-Aldrich Italy). Semithin (0.5 μm) transverse 
sections were stained with toluidine blue and analyzed with an Axioskop 200 
microscope (Zeiss, Gottingen, Germany), at final 1500x magnification. 
Morphological alterations of the peripheral nervous system were assessed 
qualitatively and quantitatively. 5 sections for each animal’s nerve were analyzed, 
and at least 25 fields for each section, corresponding to 25% of the total nerve area, 
were acquired (Mayhew and Sharma, 1984). Then number of myelinated fiber per 
fields was then counted. 
 
ELECTRON MICROSCOPY  
 
For the experiments described in chapter 1, ultra-thin sections (60–90 nm) for 
ultrastructural observations were obtained from each sciatic nerve used for light 
microscopy. Sections were collected on formvar film coated grids with a single 
hole, counterstained with lead citrate, and examined with a EM10 electron 
microscope (Zeiss).  
 
IMMUNOFLUORESCENCE  
 
For the experiments described in chapter 1, sciatic nerves were fixed in a 4 % 
paraformaldehyde (PFA) solution in phosphate buffer saline (PBS, all Sigma-
Aldrich Italy). Fixed nerves were then dehydrated through subsequent incubation 
in sucrose solution (7.5%, 15% and 30% m/v) and included in O.C.T. (Tissue-Tek, 
Torrance, CA). 10 μm thick transverse frozen sections were cut with a cryostat 
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microtome. Nerve sections were incubated 30 min at room temperature in presence 
of Fluoromyelin red (Life Technologies Italy, Monza, Italy), diluted 1:200 in a 
buffer constituted by 0.25% m/v bovine serum albumin (BSA), 0.1% m/v Triton-
X-100 in PBS. Slides were then incubated overnight at 4°C with an anti-CD68 
primary antibody produced in mouse (Abcam) diluted 1:200 in the same buffer. The 
following day, slides were washed three times in PBS and incubated 2 h with the 
specific goat anti-mouse FITC-antibody (Sigma-Aldrich Italy), diluted 1:200 in the 
buffer described above. After washing, slides were mounted using Vectashield𝑇𝑀 
(Vector Laboratories, Burlingame, CA), which contains 4',6-diamidino-2-
phenylindole (DAPI). Controls for specificity included a lack of primary antibody. 
Confocal microscopy was carried out using a LSM 510 microscope (Zeiss). 
For the experiments described in chapter 2 and 3, cells were grown on poly-L-lysine 
coated coverslips, washed with PBS and then fixed with 4% PFA. They were 
blocked for 1 hour using a 0.25% m/v BSA solution in PBS and then incubated 
overnight with the following primary antibodies, all produced in rabbit, diluted at 
the following concentrations in a BSA 0.1% m/v solution in PBS: pPKCε (Abcam), 
mPRα (Sigma-Genosys) and mPRβ (Sigma-Genosys) were diluted 1:200, mPRδ 
(Sigma-Aldrich) was diluted 1:100. Coverslips were washed three times in PBS and 
cells were incubated with the specific secondary antibody goat anti-rabbit Alexa 
488 (Life Technologies, Carlsband CA) diluted 1:500. After washing, coverslips 
were mounted using VectashieldTM. Controls for specificity included a lack of 
primary antibody. For the experiments described in chapter 2, the same confocal 
microscope mentioned above was used. For the fluorescence microscopy 
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experiments described in chapter 3, an Eclipse TE2000-U (Nikon) light microscope 
was used. 
 
BINDING ASSAY 
 
For the experiments describe in chapter 3, specific mPR binding to plasma 
membranes was assessed. Two-point competitive binding assays were conducted in 
triplicate, with plasma membranes (prepared as described above) being incubated 
for 30 min at 4° with cold progesterone, O2 and R5020 (at 10 μM and 1 μM 
concentrations), and 4 nM [3H]-progesterone. At the same time, they were also 
incubated with 4 nM [3H]-progesterone and vehicle (ethanol) to determine total 
binding. Bound [3H]-progesterone was separated from free by rapid filtration over 
Whatman GF/B filters using a 36-well cell harvester (Brandel, Gaithersburg, MD) 
and radioactivity bound to the filters counted in a liquid scintillation counter. Data 
were expressed as displacement, that is the percentage of the total binding observed 
in samples with cold compounds. 
 
IN VITRO WOUND HEALING ASSAY  
 
For the experiments described in chapter 3, the wound healing assay (Liang et al., 
2007) was performed. Cells were plated on 12-wells multiwell plates and cultured 
overnight in serum-free condition as described above. The following day, the 
wound was created making a scratch on the bottom of the multiwell plate with 200 
μL pipette tip and cells were treated with drugs as described above. Cells were then 
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photographed in phase contrast with the Eclipse TE2000-U microscope (Nikon) at 
different time points: 2, 4, 6, 8 and 24 hours after the scratch. The distances between 
cell fronts were measured with the Image J software (NIH), considering at least 
nine measurements from the top to the bottom of the well. Data are expressed as 
migrated distance, that is the difference between the initial gap between cell fronts 
and the same distance at a given time point.  
 
DATA ANALYSIS AND STATISTICS 
 
All the described experiments were repeated at least three times. 
Data were statistically evaluated using Prism 4.0 (GraphPad, San Diego, CA) and 
Systat 12 (Systat Inc., Chicago, IL) softwares. Significance was determined, 
depending on the experimental design, by two-tailed unpaired t-test, one-way 
ANOVA or two-way ANOVA. When one-way ANOVA was used, single 
conditions were then compared among them with Tukey’s post-hoc test. When two-
way ANOVA was used, single conditions were compared among them with 
Bonferroni’s post-hoc test. 𝑃 values < 0.05 were considered significant. All results 
are expressed as mean ± standard error of the mean (SEM). 
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Results and Discussion 
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CHAPTER 1 
 
Modulation of the GABAergic system as a strategy to promote nerve 
regeneration and cross-modulation of GABA receptors in the 
peripheral nervous system  
 
PART I - GABA-B LIGANDS AS POTENTIAL PHARMACOLOGICAL 
APPROACH FOR NERVE REGENERATION 
 
In order to study the effects of GABA-B ligands as a pharmacological tool to 
promote nerve regeneration after peripheral nerve lesion, we used the experimental 
model of PSL. This is a consolidated model of neuropathic pain. Indeed, the model 
mimics many typical signs (such as the rapid onset of allodynia) of the complex 
regional pain syndrome type II (CRPS-II) in humans, that is a chronic pain 
condition associated with nerve injuries (Seltzer et al., 1990). Another interesting 
advantage of the model is that it induces a denervation process that seems to affect 
in the same way axons of all sizes (Bennett et al., 2003). The morphological 
consequences of PSL have never been studied in detail in previous studies. 
The sciatic nerve was exposed and then ligated with a suture that crossed the nerve 
approximately at 1/3 of its diameter. Morphological evaluation performed after 
seven days revealed that sham operated animals had a normal nerve morphology, 
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while PSL animals presented typical signs of myelin disruption and axonal atrophy 
(Figure 13). 
 
Figure 13 – Morphological evaluation of sham and PSL animals’ sciatic nerves coronal sections 7 
days after surgery. While sham animals (A) present normal nerve morphology, PSL animals (B) 
show clear signs of axonal and myelin degeneration. 
 
Then, we evaluated the effects of pharmacological treatments on PSL animals 
morphology. We counted the number of myelinated fibers per field, as an index of 
nerve integrity. As shown in figure 14, 7-day treatment with the specific GABA-B 
agonist baclofen had no effect on the number of myelinated fibers. GABA-B 
specific antagonist CGP56433 was able to significantly up-regulate myelinated 
fibers per field. Surprisingly, the co-administration of the two drugs had an additive 
effect, increasing myelinated fibers number more CGP56433 alone (Figure 14). The 
positive effect of the co-treatment on nerve morphology was confirmed also by 
electron microscopy analysis, which revealed the presence of normal myelinated 
large fibers and small thinly myelinated regenerating ones (Figure 15).  
In order to understand if the morphological changes observed could be ascribable 
to a direct effect on Schwann cells, we also analyzed the gene expression of 
important myelin markers. 
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Figure 14 – Morphological evaluation of sciatic nerves coronal sections after 7 days of treatment. 
Macrophages are evidenced by arrowheads. A: sham; B: PSL; C: PSL + Bac; D: PSL + CGP56433; 
E: PSL + Bac + CGP56433; F: number of myelinated fibers per field in each condition. PSL induces 
a dramatic reduction of the number of myelinated fibers, and baclofen alone does not affect their 
number. CGP56433 alone significantly increase the number of myelinated fibers, and the co-
treatment show an additive effect. Scale bar: 20 μm. ****: p < 0.0001.     
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Figure 15 – Electron microscopy image of a PSL + Bac + CGP sciatic nerve coronal section. Normal 
myelinated large fibers and small thinly myelinated regenerating fibers are shown. Scale bar: 10 μm. 
 
In particular, we assessed the expression levels of P0 and PMP22 glycoproteins by 
RPA. Both glycoproteins are important constituents of the myelin sheath, required 
in particular for the stabilization of compact myelin, whose quantitative changes 
may alter Schwann cell development, growth, and differentiation (Suter and 
Scherer, 2003; Salzer, 2015). Expression of both proteins was significantly down-
regulated in PSL-operated rats. Baclofen treatment alone did not prove able to lead 
to any change in their expression. Interestingly, CGP56433 treatment increased P0 
and PMP22 expression to a level similar to Sham operated animals, while the co-
treatment showed only a partial effect, with expression levels that are intermediate 
between CGP56433 treatment and PSL (Figure 16).  
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Figure 16 – RPA evaluation of P0 (A) and PMP22 (B) mRNA expression. In both cases, CGP56433 
induces a significant up-regulation of both myelin proteins RNA. Baclofen has no effect, and the 
co-treatment shows only a partial effect. *: p < 0.05; **: p < 0.01; ***: p< 0.001.   
 
We also evaluated motor functionality using the gait test, in order to understand if 
the observed improvements in nerve morphology could correlate with positive 
functional outcomes. Rats were allowed to walk in a corridor leaving a trail of 
footprints. The following parameters were analyzed: stride length and width, step 
length and area, distance between 1–5 and 2–4 toes. As shown in table 3, most 
parameters resulted to be significantly altered in PSL animals compared to Sham 
ones, confirming that the partial ligation led to a deficit of the motor function. 
Baclofen treatment alone showed different effects on different parameters, showing 
no effect on some and worsening (such as the 2-4 toes distance) or ameliorating 
(such as stride width) others. Treatment with CGP56433, alone or in co-treatment 
with baclofen, proved able to reverse most of PSL-induced changes. In particular, 
the co-administration of the two drugs seems to be the most effective 
pharmacological treatment, being able to induce functional recovery, especially for 
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1-5 and 2-4 toes distance, leading to values similar to Sham operated animals 
(Figure 17). 
 
 
Table 3 – PSL and pharmacological treatments effects on walking parameters. PSL was able to alter 
different parameters. Pharmacological treatments were able to change most of them. The co-
treatment, in particular, among other pharmacological treatments seems to restore different 
parameters to sham level.  
 
Lastly, we evaluated the neuro-inflammatory response in the experimental model, 
assessing the presence of immunopositivity for CD68 as a marker of activated 
macrophages. Observing myelin structure, stained in red using Fluoromyelin, it is 
possible to see how PSL animals show altered myelination, that is recovered in 
animals treated with CGP56433 and with the co-administration of the two drugs, 
furtherly confirming morphological data. Observing CD68 immunopositivity in 
green, instead, it is clear how in sham animals there is no clear sign of macrophage 
activation in the nerve (Figure 18). 
 
Distance Distance Length 
1-5 toe 2-4 toe foot step
Sham 1,95 ± 0,03 1,06 ± 0,03 3,21  ± 0,09 3,64  ± 0,06 11,46  ± 0,49 1,79  ± 0,08
PSL 0,76  ± 0,04 0,5  ± 0,03 4,39  ± 0,13 4,59  ± 0,11 13,32  ± 0,54 1,9  ± 0,17
p =0.000116 p =0.000131 p =0.000116 p =0.000119 p =0.404063 p =0.968606
PSL + Baclofen 0,7  ± 0,05 0,35  ± 0,03 4,1  ± 0,18 3,85  ± 0,15 9,6  ± 0,71 1,06  ± 0,14
p =0.921960 p =0.547398 p =0.648819 p =0.002619 p =0.018476 p =0.000914
PSL + CGP56433 1,42  ± 0,05 0,86  ± 0,03 2,61  ± 0,12 3,28  ± 0,11 9,29  ± 0,64 1,13  ± 0,20
p =0.000116 p =0.000135 p =0.000113 p =0.000117 p =0.018430 p =0.005125
PSL + Baclofen + 1,58 ± 0,09 0,98  ± 0,04 3,51  ± 0,12 3,63  ± 0,15 10,16  ± 0,93 1,51  ± 0,11
CGP56433 p =0.000116 p =0.000131 p =0.000466 p =0.000129 p =0.056044 p =0.289398
Stride width Stride length Area touched
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Figure 17 – 1-5 (A) and 2-4 (B) toe distance. PSL significantly reduces both parameters, indicating 
motor impairment. Baclofen alone has no effect, while CGP56433 alone proved able to restore both 
parameters to a level closer to the sham group. Again, the co-treatment showed a stronger recovery 
than CGP56433 alone, suggesting an additive effect. ***: p < 0.001. 
 
In PSL and baclofen treated animals, instead, clear signs of macrophage infiltration 
are present, with merged images showing infiltrated macrophages inside the myelin 
structure, suggesting a general increase in neuro-inflammation. CD68 
immunopositivity resulted to not be present in CGP56433 animals, both in single 
treated and co-treated ones, suggesting that only the GABA-B antagonist may be 
able to reduce neuro-inflammation following peripheral nerve injury (Figure 18). 
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Figure 18 - Immunofluorescence images of sciatic nerves coronal sections. Myelin structures are 
evidenced in red with Fluoromyelin. Macrophages specific marker CD68 is in green. Nuclei are 
stained in blue with DAPI. PSL causes an inflammatory response, as evidenced by CD68 activation. 
Baclofen has no effect on it, while CGP56433 proved able to counteract it.  Scale bar: 20 µm. 
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PART II - GABA-A SUBUNITS MODULATION IN GABA-B1 KNOCKOUT 
MICE PERIPHERAL NERVOUS SYSTEM 
 
Different lines of evidence suggest that GABA-A and GABA-B receptors may be 
involved in an important functional cross-talk in the peripheral nervous system, and 
in particular in Schwann cells (recently reviewed in Faroni and Magnaghi, 2011). 
GABA-A activation, for example, proved able to exert an effect on GABA-B 
expression and responsiveness (Magnaghi et al., 2006, 2010). On the other hand, 
GABA-B specific deletion in Schwann cells had an important effect in conditional 
knockout (P0-CRE_GABA-B1fl/fl) animals, inducing biochemical, functional and 
morphological modifications, also with alterations in pain sensitivity (Faroni et al., 
2014). 
Therefore, in order to better characterize the experimental model, and to deepen our 
knowledge on the interactions between the two receptors in the peripheral nervous 
system and on non-autonomous effects exerted by GABA-B deletion in Schwann 
cells, we analyzed (by qRT-PCR) GABA-A subunits mRNA expression in the DRG 
total tissue harvested from P0-CRE_GABA-B1fl/fl mice and in DRG neurons 
primary cultures obtained from the same animals.  
The first step was the evaluation of the basal expression of selected GABA-A 
subunits in control mice, analyzing also sciatic nerves and Schwann cell primary 
cultures. In particular, we focused our attention on subunits typically present in 
extra-synaptic receptors, about whom interest rose in recent years (Belelli et al., 
2009; Fritschy and Panzanelli, 2014) and were not previously characterized in the 
peripheral nervous system. As shown in table 4, δ, α4 and α5 subunits were found 
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to be present in DRG, sciatic nerves, DRG neurons and Schwann cells. Looking at 
the relative expression level of considered subunits, it can be noticed that synaptic 
subunits (α2 and γ2) appear to be more expressed in DRG total tissue and neurons, 
while extra synaptic ones (α4, α5 and δ) seem to be in general more expressed in 
sciatic nerves and, partially, in Schwann cells.  
 
Table 4- GABA-A subunits relative expression in DRG tissue (DRG tot), DRG neurons, sciatic 
nerves and Schwann cells (SCs). Synaptic subunits resulted to be more expressed in DRG tissue and 
neurons, extra-synaptic ones in sciatic nerves and Schwann cells. Relative expression level (R.e.l.): 
+: R.e.l. < 5; ++: 5 < R.e.l. < 50; +++: 50 < R.e.l. < 500; ++++: 500 < R.e.l. <1000; +++++: R.e.l. > 
1000. 
 
We then evaluated the expression levels of 9 different GABA-A subunits (α2, α3, 
α4, α5, β1, β2, β3, γ2, δ) in DRG neurons and tissue extracts of experimental and 
control animals. Data show a clear tendency to down-regulation of several subunits 
both in tissue extracts and neuronal cultures (Figure 19), suggesting a general 
reduced number of GABA-A receptors in conditional knockout animals DRG. In 
both cases, α3 and β1 subunits resulted to be significantly down-regulated. β2 and 
β3 were significantly down-regulated in tissue extracts, but showed only a tendency 
to down-regulation in primary cultures. α2 and γ2 subunits showed a tendency to 
down-regulation in both cases, but this difference was not statistically significant, 
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although in tissue extracts the difference for γ2 is at the very limit of statistical 
significance (p = 0.05). Some differences can be noted for extra synaptic subunits; 
indeed, while in tissue extracts α4, α5 and δ subunits did not result to be modulated 
(Figure 19A), in neuronal primary cultures α4 and δ resulted to be significantly 
down-modulated, suggesting this may be a neuron-specific change (Figure 19B).  
 
Discussion 
 
The identification of new treatments for nerve regeneration and chronic neuropathic 
pain is currently a challenge for clinical neurologists, and possible improvements 
in therapy mostly rely on the comprehension of the mechanisms underlying these 
pathologies. 
As mentioned above, PSL is an established model for the study of neuropathic pain. 
However, the morphological consequences of PSL treatment and its impact on 
Schwann cell molecular parameters, such as the expression of the two main myelin 
proteins, P0 and PMP22 (Quarles, 2002; Salzer, 2015), were poorly understood. A 
severe degeneration of the nerve structure was observed, with loss of large 
myelinated fibers, nerve de-myelination, and phagocytosis. P0 and PMP22 
expression was strongly decreased, confirming a massive degenerative process 
affecting peripheral nerves myelin forming compartment. According to the 
literature (Bennett et al., 2003), the nerve degeneration was expected to be equal 
for axons of all sizes, affecting either myelinated (type Aβ/Aδ) and unmyelinated 
(type C, mostly nociceptors) fibers. 
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Figure 19 – GABA-A subunits mRNA expression in DRG tissue extract (A) and neuronal cultures 
(B). A clear tendency to down-regulation can be observed in conditional knockout (cKO) mice. *: 
p < 0.05; **: p < 0.01; ***: p < 0.001. 
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The putative therapeutic effect of two GABA-B ligands on the altered behavioral, 
biochemical, and morphological parameters of the PSL model has been 
investigated. The choice to use baclofen as a GABA-B ligand relies on previous 
findings demonstrating the involvement of GABA-B receptors in the control of 
Schwann cell biology, being involved in their differentiation, in myelination and in 
nociception (Magnaghi et al., 2004, 2008; Procacci et al., 2012; Faroni et al., 2013). 
Moreover, baclofen showed anti-allodynic and anti-nociceptive actions in chronic 
pain models in rats (Cui et al., 1998; Patel et al., 2001). Baclofen was also used in 
a limited number of clinical trials to treat some types of neuropathic pain, including 
the use of spinally administered baclofen to enhance spinal stimulation effects 
(Fromm, 1989; Hering-Hanit, 1999; Lind et al., 2004). However, its use was limited 
because of its sedative properties and the rapid development of tolerance. 
CGP56433 is a high affinity antagonist of the GABA-B receptor, active at 
nanomolar concentration in numerous in vitro and in vivo studies (de Groote et al., 
1999; Froestl, 2010). Present results are the first to show CGP56433 effects linked 
to peripheral nerve regeneration.  
Surprisingly, the agonist baclofen and the antagonist CGP56433 exerted an additive 
effect. This is not a common phenomenon in the nervous system. However, a 
GABA-B ligands additive effect on brain stimulation rewards has been previously 
described. Indeed, the GABA-B agonist CGP44532 and the antagonist CGP56433 
induced a reward decrement when administered separately, while their co-
administration induced an additive effect on threshold, rather than blocking the 
agonist-induced threshold elevations (Macey et al., 2001).  
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In the present model, part of the effects achieved with CGP56433 treatment alone 
may result from the blocking of GABA-B receptor activation by endogenous 
GABA, that, as previously mentioned, can be synthesized and released by Schwann 
cells (Magnaghi et al., 2010). Schwann cells, indeed, resulted to be particularly 
responsive to CGP56433, revealing a specific effect mediated by the GABA-B 
receptors present on their cell surfaces. The GABA-B antagonist significantly up-
regulated P0 and PMP22 mRNA level, in line with previous findings indicating that 
GABA-B activation leads to myelin proteins decreased expression (Magnaghi et 
al., 2004). Present findings suggest that the additive effects exerted by baclofen and 
CGP56433 may be the result of a double simultaneous action; indeed, CGP56433 
may act through the myelin-forming component, while baclofen likely acts through 
the neuronal (central and/or peripheral) compartment. Given the additive effects on 
locomotor parameters, the activation of mixed central and peripheral targets should 
not be excluded. Interestingly, CGP56433 alone partially recovered the 1–5 and 2–
4 toes distances, suggesting that these effects may be ascribed to the antagonism of 
the GABA-B mediated tonic control of motor coordination.  
Macrophages are committed to neuroimmune surveillance in the peripheral nervous 
system, and intervene during the Wallerian degeneration following axonal injury 
(Faroni et al., 2015). Macrophages concur to the onset of pain hyperactivity, 
therefore a reduction in their recruitment is beneficial (Scholz and Woolf, 2007). 
The reduced recruitment observed following CGP56433 and CGP56433-baclofen 
treatments is in agreement with a protection against neuroimmune-induced 
neuropathic pain, revealing that only the GABA-B antagonist is active in this 
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context. This effect is likely due to a direct effect on macrophage cells, which 
express the GABA-B receptor (Tamura et al., 2007).  
Even if most of the effects described derive from a direct action of drugs on 
peripheral components, the involvement of central pathways should not be 
excluded. It is indeed reported that central mechanisms of GABA ligands, 
administered intrathecally, equally affect the behavioral signs of neuropathy 
(Hwang and Yaksh, 1998; Malan et al., 2002).  The possibility to administer 
GABA-B ligands in situ, close to the nerve injury site, is therefore an opportunity 
which deserves further investigation. 
Different studies suggest that GABA-A and GABA-B receptor are involved in a 
complex cross-interaction in the peripheral nervous system, often exerting opposite 
effects on Schwann cells (reviewed in Faroni and Magnaghi, 2011).  
The basal expression level of some GABA-A subunits has been previously 
investigated in rat sciatic nerves and Schwann cells, suggesting for example that α1 
and α6 subunits may be not importantly expressed in peripheral nerves (Magnaghi 
et al., 2006). However, extra-synaptic subunits expression was never assessed, 
therefore this is the first evidence about the expression of these subunits in 
peripheral glial cells. GABA-subunits expression in mature oligodendrocytes has 
recently been analyzed (Arellano et al., 2016). In this study, the subunits more 
importantly expressed resulted to be α3, β2, β3, γ1 and γ3, with the δ subunit being 
expressed at very low levels, if not at all. This suggests a different subunits 
composition between the myelinating cells of the peripheral and the central nervous 
system. In particular, the most important difference seems to be the fact that 
Schwann cells express extra-synaptic subunits, and in particular the δ subunit, 
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important for neuroactive steroids affinity (Belelli and Lambert, 2005); Conversely, 
oligodendrocytes express almost only synaptic subunits. Therefore, taken together 
these data suggest that Schwann cells and oligodendrocytes express GABA-A 
receptors with different subunits composition, thus displaying a different 
pharmacological profile.  
Present data suggest that synaptic receptors may be more importantly expressed in 
DRG, while extra-synaptic ones seem to be predominant in sciatic nerves and, 
partially, in Schwann cells. This is in line with data previously reported for DRG, 
where the most common receptor composition was found to be α2β3γ2 (Ma et al, 
1993; Liu et al., 2004). Another interesting point is that subunits expression seems 
to be almost overlapping between DRG tissue and neurons, and deeply different 
between Schwann cells and sciatic nerves, suggesting that in both cases GABA-A 
receptors may be more expressed in the neuronal compartment. However, for what 
regards the discrepancy between sciatic nerves and Schwann cells, the possibility 
that part of the observed difference may be due to the different Schwann cell 
differentiation state cannot be ruled out; Schwann cells in sciatic nerves are still in 
contact with their axons, and therefore may be mostly myelinating, while cultured 
Schwann cells are not in contact with the neuronal compartment, and may show 
mostly a non-myelinating phenotype.  
Even if some studies reported the GABA-A- mediated modulation of GABA-B 
expression (Magnaghi et al., 2006), little is known about GABA-A modulation by 
GABA-B activation/de-activation. Moreover, the analysis of GABA-A receptor 
modulation in the P0-CRE_GABA-B1fl/fl model may help to understand some of 
the variations observed (Faroni et al., 2014). 
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Observing GABA-A subunit expression in DRG total tissue extracts and neurons, 
it is evident how these animals show a general GABA-A down-regulation. This 
evidence suggests a reduced GABAergic inhibitory tone, which may contribute to 
the hyperalgesic and allodynic state observed (Faroni and Magnaghi, 2014). Indeed, 
increased DRG neurons excitability was reported to play a role in the initiation and 
maintenance of central sensitization, that is an important contributor to the 
development of neuropathic pain (Julius and Basbaum, 2001). It was also reported 
that the neuropathy following peripheral nerve injury involves GABA-A reduced 
expression in sensory neurons (Obata et al., 2003). Moreover, α2 subunit silencing 
in rat DRG proved able to worsen mechanical and thermal hypersensitivity in crush-
injured rats, as well as endogenous GABA up-regulation alleviated neuropathic 
pain symptoms (Obradovic et al., 2015).    
Analyzing with more attention which subunits are involved in this modulation, it 
seems clear that GABA-B conditional knockout in Schwann cells has a greater 
effect on synaptic receptors in DRG total extracts, while extra-synaptic ones do not 
seem to be modulated. Therefore, the hypothetical reduced GABAergic tone in 
DRG may regard mainly a reduction in phasic synaptic currents. However, the 
strong specific reduction of α4 and δ subunits (typical constituents of the most 
common extra-synaptic receptor sub-type, Fritscy and Panzanelli, 2014) in DRG 
neurons, but not in the total tissue extract, may suggest a specific down regulation 
of δ containing extra-synaptic receptors, while α5-contaning seem to be not 
modulated. These different sub-types of extra-synaptic receptors have different 
characteristics; in particular, δ-containing GABA-A receptors have high affinity for 
GABA and neuroactive steroids, being the most important target of 
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allopregnanolone action (Belelli et al., 2009, Carver and Reddy, 2013). Alteration 
of their expression levels have been correlated with nociception in spinal neurons 
(Bonin et al., 2011), but their role in DRG has not been elucidated yet. Altogether, 
these data shed some light on GABA-A receptors composition in the peripheral 
nervous system, suggesting for the first time the presence of extra-synaptic subunits 
in Schwann cells, giving a possible explanation for the altered nociception observed 
in P0-CRE_GABA-B1fl/fl mice.  
 
Some of the results presented in this chapter are published in the following 
article: 
Magnaghi V*, Castelnovo LF*, Faroni A, Cavalli E, Caffino L, Colciago A, 
Procacci P, Pajardi G (2014) Nerve regenerative effects of GABA-B ligands in a 
model of neuropathic pain BioMed Res Int 2014:368678. 
*equally contributing 
Other results will be submitted for publication in an article currently in 
preparation. 
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CHAPTER 2 
 
Study of PKCε modulation by allopregnanolone in the peripheral 
nervous system as a possible strategy for neuropathic pain treatment 
 
Strong evidence supports the hypothesis that PKCε is importantly involved in the 
modulation of neuropathic pain, given its ability to phosphorylate both excitatory 
(such as TRPV1 and N-type Ca++channels) and inhibitory (such as GABA-A and 
opioid μ) receptors. (Olah et al., 2002; Morenilla-Palao, 2004; Narita et al., 1997; 
Zhang et al., 2004, Van Kolen et al., 2008). Moreover, some data suggest it may be 
involved in a cross-interaction with allopregnanolone and the GABA-A receptor 
(Puia et al., 2015), which has not been clearly elucidated yet.  
The first step of our study was the qRT-PCR evaluation of PKCε relative expression 
in Schwann cell and DRG neuron primary cultures. As expected, PKCε resulted to 
be more expressed in neurons, but it resulted to be significantly expressed also by 
Schwann cells (Figure 20).  
Then, we analyzed how PKCε expression was modulated by allopregnanolone 
treatment. In particular, we treated Schwann cell and DRG neuron primary cultures 
for 24 h with allopregnanolone at 1 μM concentration. We also performed 
conditioned medium experiments, in which Schwann cells were treated for 24 h 
with allopregnanolone, and then their medium was used to treat DRG neurons for 
24 h.  
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Figure 20 – PKCε mRNA relative levels in DRG neurons (DRG) and Schwann cell (SCs) primary 
cultures. Even if the expression is higher in DRG neurons, also Schwann cells express PKCε. 
 
Allopregnanolone treatment proved able to induce a significant down-regulation of 
PKCε expression in Schwann cells (Figure 21A), while it exerted no effect on DRG 
neurons (Figure 21B). Interestingly, in neurons treated with Schwann cells 
conditioned medium, PKCε expression was significantly increased (Figure 21C), 
suggesting that allopregnanolone may modulate PKCε expression in DRG neurons 
through a Schwann cell-mediated mechanism. PKCε modulation in Schwann cells 
and conditioned medium-treated DRG neurons was confirmed also at the protein 
level, with Western blot in Schwann cells and immunofluorescence in Schwann 
cells and neurons. In particular, in Schwann cells, the Western blot confirms PKCε 
expression down-regulation (Figure 21D), while the immunofluorescence analysis, 
targeting the active PKCε phosphorylated form (pPKCε) suggested a possible 
increase in its phosphorylation (Figure 21E-F). Immunofluorescence analysis of 
conditioned medium experiments, instead, showed an increased immunopositivity 
for pPKCε, suggesting that the up-regulation observed in the mRNA levels leads 
also to higher levels of the active form on the cell membrane (Figure 21G-H). 
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(caption in the next page) 
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Figure 21 (previous page) – Results of allopregnanolone (THP) treatments on Schwann cells, DRG 
neurons and conditioned medium experiments. Allopregnanolone was able to induce a significant 
down-regulation of PKCε gene expression in Schwann cells (A), but was not effective on neurons 
(B). Schwann cells conditioned medium, however, induced a significant up-regulation of PKCε 
mRNA levels in DRG neurons (C). PKCε down-regulation in Schwann cells was confirmed also by 
Western blot analysis (D); however, pPKCε signal appears to be stronger in allopregnanolone-
treated Schwann cells (F), compared to control (E). The treatment with Schwann cells conditioned 
medium was also able to induce a stronger immunopositivity for pPKCε (G: control; H: 
allopregnanolone treatment). *: p < 0.05; **: p < 0.01; ****: p < 0.0001;  
 
Discussion 
 
The peripheral mechanisms regulating neuropathic pain, although under extensive 
study, are not yet completely clear and need further investigation. Some evidence 
suggest that PKCε may be involved in this process. Indeed, it is present in DRG 
neurons., where it was reported to alter the permeability of N-type Ca++ channels 
and enhance nociception (Van Kolen et al., 2008). In the present study, its 
expression in DRG neurons has been confirmed, and moreover it was found to be 
significantly expressed also by Schwann cells, even if at a lower level compared to 
DRG neurons. PKCε basal expression in Schwann cells was previously hinted in 
some studies (Borghini et al., 1994; Kawano et al., 1997), but was never properly 
characterized in physiological conditions.  
Pharmacological treatments revealed that allopregnanolone was able to reduce 
PKCε mRNA and protein levels in Schwann cells; however, immunofluorescence 
analysis suggests an up-regulation of its phosphorylation and trafficking to the cell 
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membrane. The physiological importance of this effect is still not clear. There is 
evidence in literature that the infection by the causative organism of leprosy, 
Mycobacterium leprae, is able to induce the activation of the Erk 1-2 pathway 
through a PKCε-dependent mechanism, leading to increased Schwann cell 
proliferation (Tapinos and Rambukkana, 2005). Allopregnanolone has been 
reported to modulate Schwann cell proliferation through a mechanism involving 
GABA-A binding and EAAC1 glutamate transporter trafficking (Perego et al., 
2012). Therefore, the possibility that this effect is partially regulated by PKCε 
modulation deserves further investigation. 
Allopregnanolone treatment did not  change PKCε expression in DRG neurons, but 
neurons treated with Schwann cell conditioned medium showed an increased PKCε 
expression and phosphorylation. This evidence may appear in contrast with a 
consistent number of paper, that suggested a possible role for allopregnanolone in 
neuropathic pain reduction (reviewed in Patte-Mensah et al., 2014). However, it is 
important to notice that some in vitro data suggest that the activation of GABA-A 
receptors in DRG may be excitatory, because of a higher Cl- concentration in the 
intracellular compartment, and hence potentially responsible for painful behavior 
(Aptel et al., 2007). There is also some electro-physiological evidence suggesting 
that, in a subset of human unmyelinated sensitive fibers, GABA may lead to 
depolarization (Carr et al., 2010). Therefore, increased PKCε activity, considering 
its ability to de-sensibilize GABA-A (McMahon and Koltzenburg, 1990; Si et al., 
2004; Yamada et al, 1996; Ma et al., 2006), may indeed lead to hyper-polarization 
of at least a subset of sensitive fibers, possibly mediating an anti-nociceptive effect. 
However, as mentioned above, the GABA-A receptor has also been reported to be 
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down-regulated after nerve damage (Obata et al., 2003), and its down-regulation in 
DRG neurons might exacerbate hyperalgesic reactions after crush injury in rats 
(Obradovic et al., 2015). Therefore, the effective role of GABA-A activation in 
DRG during neuropathic pain is far from being elucidated, and will require further 
investigation, probably involving different actions, which might be exerted by 
different GABA-A receptor sub-types (Obradovic et al., 2015; Bravo-Hernandez et 
al., 2014, 2016).  
Taken together, these findings support the hypothesis of a GABA-
A/PKCε/allopregnanolone cross-correlation in the peripheral nervous system, 
strengthening the role of neuron/glia cross talk in the modulation of neuropathic 
pain. 
 
Some of the results presented in this chapter are published in the following 
article: 
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and 
allopregnanolone: functional cross-talk at the GABAA receptor level Front 
Cell Neurosci 9:83. 
Other results will be submitted for publication in an article currently in 
preparation. 
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CHAPTER 3 
 
Characterization of the expression in Schwann cells of novel non-
classical membrane progesterone receptors (mPRs and PGRMC1) 
and evaluation of their potential role in the modulation of Schwann 
cell physiology 
 
In the last decades, an increasing amount of data in literature dealt with the 
important role of progestogens in the nervous system. It is well known that 
progesterone and DHP bind the classical PR, while allopregnanolone exerts its 
action through the GABA-A receptor (Belelli and Lambert, 2005). However, these 
two mechanisms of action are not sufficient to explain all the actions exerted by 
progestogens in the nervous system. 
A new class of membrane progestogen receptors, mPRs, was originally identified 
in seatrout ovaries by Thomas and colleagues (Zhu et al., 2003a, b), and was 
subsequently shown to be functionally present in the central nervous system 
(reviewed in Guennoun et al., 2015). The presence and role of these receptors, 
however, has never been deeply investigated in the peripheral nervous system, and 
in particular in Schwann cells. 
For this line of experiments, we used a commercially available Schwann cell line 
(S42), directly derived from rat primary Schwann cell cultures (Toda et al., 1994). 
We decided to use these cells instead of primary Schwann cells for both ethical and 
practical reasons; we preferred to use this model because we thought it was suitable 
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for a first characterization of mPRs expression in Schwann cells, reducing the 
number of animals used in our research, as well as the economic cost. 
The first goal of our research was to demonstrate the mRNA expression of the five 
mPR sub-types (mPRα, β, γ, δ and ε) and PGRMC1 in the S42 Schwann cell line, 
using RT-PCR analysis. As shown in figure 22A, all receptors were significantly 
expressed. mPRα, β, δ and PGRMC1 were highly expressed, while mPRγ and ε 
were lowly expressed. The presence of the proteins encoded by these genes has 
been confirmed by Western blot on membrane enriched protein extracts, suggesting 
that the receptors are not only expressed, but also localized on the cell membrane 
(figure 22B) All the receptors, with the exception of mPRδ, were detected at a 
molecular weight around 60-80 Kda, almost double than expected, as previously 
reported in rat brain (Zuloaga et al., 2012).  
 
(Caption in the next page) 
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Figure 22 (previous page) – Characterization of mPRs and PGRMC1 expression in S42 Schwann 
cells. All receptors resulted to be expressed both at the mRNA (A) and protein (B) level. In 
particular, RT-PCR suggests that mPRα, β, δ and PGRMC1 are more expressed than mPRγ and ε. 
The fact that all receptors were detected in Western blot in membrane enriched fractions suggests 
their functional presence on the cell membrane.    
 
We then measured the basal expression levels of different mPR isoforms and 
PGRMC1 through qRT-PCR. mPRβ, PGRMC1 and mPRδ resulted to be the most 
expressed receptors; mPRα was expressed at lower levels, while the expression 
levles of mPRγ and mPRε are almost neglectable (Figure 23). 
 
Figure 23 – qRT-PCR analysis of different mPR isoforms and PGRMC1 in S42 Schwann cells. 
mPRβ, mPRδ and PGRMC1 are higly expressed, while mPRγ and mPRε are present at extremely 
low levels, and mPRα is present at an intermediate level 
 
We then performed an immunocytochemical evaluation of the cell localization of 
the highly expressed mPR isoforms (α, β and δ). All the receptors shown clear 
immunopositivity, but they appeared to be expressed both on the plasma membrane 
and in the cytoplasm (Figure 24).  
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Figure 24 – Immunocytochemical evaluation of mPRα, β and δ expression in S42 Schwann cells. 
The three isoforms seem to be present both on the cell membrane and in the cytoplasm. 
 
To confirm specific membrane localization, necessary for the functionality of the 
receptors, we repeated Western blot experiments including a glucose pad 
centrifugation step in the membrane preparation, in order to verify the effective 
expression of mPRs and PGRMC1 on the cell membrane of the S42 Schwann cell 
line model (Figure 25). 
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Figure 25 – Western blot analysis of mPRs expression in S42 Schwann cells after extraction 
including a centrifuge step with sucrose pad. The presence of specific bands in membrane extract 
after the further purification steps corroborates the hypothesis of their membrane expression. 
 
In order to furtherly demonstrate the effective expression of functional mPRs on 
the cell membrane, we performed a two-point competition binding assay, analyzing 
the ability of progesterone, the specific mPR ligand O2 and the PR specific ligand 
R5020 to displace radioactive progesterone (3H-progesteorne) from membrane 
protein extracts. The results confirm the presence of functional mPRs on the cell 
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membrane of S42 cells, since both progesterone and O2, but not R5020, resulted 
able to displace 3H-progesterone (Figure 26). 
 
 
Figure 26 – Binding assay. Both cold progesterone (P4) and O2, but not R5020, are able to displace 
3H-progesterone, indicating that the binding is specific to mPRs and does not involve PR. *: p<0.05; 
**: p<0.01;  ***: p<0.001, compared to vehicle. 
 
Once confirmed mPRs functional presence on the plasma membrane, we analyzed 
mPR proteins levels on the cell membrane after treatment with their specific 
agonist. Therefore, we treated S42 Schwann cells with O2 for 12 hours, and then 
we incubated cells in serum-free condition before membrane preparation; 
otherwise, receptors may have been internalized, preventing a reliable identification 
of their level (Foster et al., 2010). We evaluated mPRα, β and δ expression levels 
by Western blot. We did not observe significant changes in the protein level of any 
receptor (Figure 27).   
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Figure 27 – mPR proteins level on the plasma membrane after O2 20 nM treatment. None of the 
receptors resulted to be modulated by the treatment with the specific agonist.  
 
We then analyzed the possible involvement of mPRs in progestogens-mediated 
modulation of Schwann cell physiology, starting with the analysis of specific 
Schwann cell protein expression modulation. Therefore, we treated cells for 24 
hours with the specific mPR agonist O2 and we analyzed possible alterations in the 
mRNA expression levels of P0, PMP22, MAG (markers of the myelinating 
phenotype) and GFAP (marker of the non-myelinating phenotype) by qRT-PCR. 
MAG resulted to be significantly upregulated, while other proteins where not 
modulated (Figure 28A).  
We expanded our analysis, treating cells with O2, progesterone and R5020 for 24 
hours and evaluating MAG expression. O2 confirmed its ability to up-regulate 
MAG gene expression, and this effect was mimicked both by progesterone and 
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R5020 (Figure 28B). O2-mediated MAG up-regulation has also been confirmed by 
Western blot analysis on total cell lysate after 36 hours of treatment (Figure 28C).   
 
(Caption in the next page) 
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Figure 28 (Previous page) – Evaluation of mPR activation with O2 20 nM treatment on Schwann 
cell proteins expression. qRT-PCR analysis revealed that, among considered targets, only MAG was 
significantly modulated (A). further analysis with progesterone (P4) 20 nM and R5020 20 nM 
suggest that this effect may be not specifically mPR-mediated (B). MAG up-regulation was 
confirmed by Western blot (C). *: p < 0.05. 
 
Lastly, in order to analyze possible effects of mPRs on S42 Schwann cell motility, 
we performed an in vitro wound healing assay, scratching the bottom of the culture 
vessel where cells were plated and observing how pharmacological treatments may 
modulate their migration into the scratch (Figure 29A). In a first preliminary 
experiment, the effect of O2 treatment was evaluated at 2, 4, 6, 8 and 24 hours after 
the scratch (Figure 29B). 24 hours data were not considered since in different wells 
the gap was closed in many points, making the analysis not reliable.  Since this first 
analysis suggested that O2 treatment may exert its action mainly after 2 and 4 hours, 
we repeated the test considering only this two time points, including also 
progesterone and R5020 treatments. The results show that the effect may be mPR 
specific, since it is mimicked by progesterone, but not by R5020 (Figure 29C).   
 
Discussion 
 
In the last two decades, several studies pointed out to an important role for 
progestogens, and in particular allopregnanolone, in the modulation of Schwann 
cell physiology, modulating several biochemical and functional parameters.  
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(Caption in the next page) 
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Figure 29 (previous page) – Assessment of mPR role on S42 Schwann cell migration. After a 
scratch is made on the bottom of their culture vessel, S42 Schwann cells progressively migrate in 
order to close the gap (A). A preliminary experiment, performed using only O2 20 nM as 
pharmacological treatment, suggested that mPR effect on S42 Schwann cell migration may be rapid, 
being evident 2 and 4 hours after the scratch (B). Further analysis of this two time points, which 
included also pharmacological treatment with progesterone (P4) and R5020 (both 20nM), suggested 
that this effect may be mPR specific, since it is mimicked by progesterone, but only partially by 
R5020 (C). 
 
In particular, it has been reported that progestogens may control Schwann cell 
proliferation, myelin proteins expression, GABA synthesis, GABA-B receptor 
modulation and glutamate trafficking (Magnaghi et al., 2001, 2006, 2009, 2010; 
Perego et al., 2012; Faroni and Magnaghi, 2011). Most of these action (regulation 
of cell proliferation, PMP22 expression, GABA synthesis, GABA-B receptor 
expression levels and glutamate trafficking) resulted to be mediated by 
allopregnanolone interaction with the GABA-A receptor, others (for example the 
modulation of P0 expression) were mediated by DHP binding with the classic PR. 
However, the exact mechanism underlying progestogens modulation of Schwann 
cell physiology is not completely clear, and other mechanisms may be involved. 
After their initial identification in seatrout ovaries (Zhu et al., 2003b), mPRs have 
been demonstrated to be present in several tissues, and in particular in the central 
nervous system, both in the brain and in the spinal cord (Zuloaga et al., 2012; Meffre 
et al., 2013; Pang et al., 2013; Labombarda et al., 2010). In physiological 
conditions, mPRs were found to be not expressd by glial cells in the brain (Meffre 
et al., 2013), and only mPRα was expressed by oligodendrocytes and astrocytes in 
the spinal cord (Labombarda et al., 2010). However, it was also reported that mPRα 
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expression is induced after traumatic brain injury in oligodendrocytes, astrocytes 
and microglia, both in the lesion core and peri-lesioned area, suggesting it may have 
a role in glia-mediated neuroprotective action of progesterone (Meffre et al., 2013).  
Taken together, these findings suggested the hypothesis that mPRs may have a role 
in the modulation of progestogens action in Schwann cells.    
In order to perform this study, we decided to use a Schwann cell line model, directly 
derived from primary rat Schwann cell cultures after many generations in culture, 
the S42 Schwann cells. These cells have been reported to resemble, under some 
aspects, Schwann cells at an early stage in their preparation for myelination, and to 
express some typical markers of Schwann cells, such as MAG, which is expressed 
at high levels, and P0, that is instead expressed at lower levels than in sciatic nerves 
(Toda et al., 1994). Compared to similar cell lines (named S16 and S16Y), S42 
Schwann cells expressed higher amounts of MAG and were characterized by slower 
proliferation (Toda et al., 1994).  
RT-PCR identification of mPRs and PGRMC1 mRNA, and the subsequent Western 
blot analysis of their presence on membrane enriched fraction, represent the first 
time mPRs have been identified in peripheral glial cells. All the receptors in 
Western blot appear to have a higher molecular weight than expected, being almost 
double. This phenomenon has been reported before in rat brain and human 
umbilical vein endothelial cells, and the authors suggested it could be linked to 
dimer formation (Zuloaga et al., 2012, Pang et al., 2015). Another possible 
explanation may be a strong glycosylation. The following qRT-PCR analysis 
showed that mPRβ and mPRδ are the more expressed mPR isoforms in S42 
Schwann cells, while mPRα is present at lower but still significant levels. These 
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findings are in line with previously reported data, identifying mPRβ as the main 
isoform in the rat brain (Zuloaga et al., 2012) and mPRδ as a specific isoform of the 
nervous system (Pang et al., 2013). 
Immunofluorescence analysis revealed that mPRα, β and δ immunopositivity is 
present on the cell membrane, but is also clearly present in the cytoplasm, 
particularly in the perinuclear area, while it is weak in cellular processes. Even if 
membrane localization was not evident, the effective presence of the receptors on 
the cell membrane was confirmed by Western blot and binding studies. Indeed, 
Western blot analysis was repeated including a sucrose pad centrifugation step to 
assure more reliable membrane fraction separation (Thomas et al., 2005; Pang et 
al., 2008), therefore confirming membrane localization of mPRα, β, δ and 
PGRMC1. This evidence was further confirmed with two-point binding assay, that 
confirmed the presence on S42 Schwann cell membranes of functional receptors 
able to bind progesterone and the specific mPR agonist O2, but not the specific PR 
agonist R5020 (Kelder et al.,2010).  
For the experiment involving pharmacological treatments, progesterone, O2 and 
R5020 were used. O2 is a specific mPR agonist; indeed, it was reported to bind 
human mPRα with higher affinity than progesterone, and even if it can bind PR, it 
has no agonist activity on it (Kelder et al., 2010). On the other hand, R5020 is a 
specific PR agonist, having little or no affinity for mPRs (Kelder et al., 2010). 
Therefore, the cell treatment with progesterone and these two compounds allows to 
discriminate between mPR and PR mediated effect.  
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In line with published data, mPRα, β and δ levels resulted to be not modulated by 
the treatment with their agonist. Indeed, progesterone treatment does not modulate 
mPRα protein levels in male mouse brain (Meffre et al., 2013). 
Schwann cell treatment with the specific mPR agonist O2 was not able to modulate 
the mRNA expression levels of P0, PMP22 (that are the main protein components 
of compact myelin, Quarles, 2002; Salzer, 2015) and GFAP (that is a marker of 
non-myelinating Schwann cells, Procacci et al., 2012). However, it proved able to 
up-regulate MAG mRNA and protein level. As mentioned above, MAG is a 
glycoprotein mainly expressed on the adaxonal membrane and in other specialized 
structures in peripheral nervous system myelin, such as Schmidt-Lanterman 
incisures (Quarles, 2002; Salzer, 2015). It is involved in myelin-axon interactions, 
having a role in the bi-directional signaling between myelin-forming glia and axons 
(Quarles, 2007). Different studies with knockout models suggested that MAG is not 
necessary for the myelination process (Quarles, 2007), however it is deputed to 
stabilize myelinated axons (Fruttiger et al. 1995; Pan et al. 2005; Nguyen et al. 
2009; Lopez et al., 2011). A recent report suggests that MAG protects neurons from 
excitotoxicity (Lopez et al., 2011).  
O2 proved able to induce MAG mRNA and protein levels up-regulation, but this 
effect does not seem to be specifically mPR mediated, being mimicked by 
progesterone and R5020. Therefore, progestogens may regulate MAG level both 
through classical and non-classical mechanisms.  
After nerve injury, myelinating Schwan cells change their differentiation status, 
assuming a phenotype that promotes nerve regeneration (Faroni et al., 2015), 
proliferating and migrating (Mantuano et al., 2015). Our data suggest that mPR 
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mediated progestogen action on Schwann cells may be important in the early stages 
of this process. Indeed, using a consolidated migration assay (Liang et al., 2007), 
we observed that O2 was able to significantly increase Schwann cell migration 2 
and 4 hours after treatment, but this effect was lost at longer time points. 
Interestingly, progesterone treatment has the same pro-migration effect, while 
R5020 does not significantly affect S42 Schwann cell migration. 
In conclusion, this line of evidence constitutes the first demonstration of mPRs 
functional expression in Schwann cells, also indicating some effects of this 
receptors activation in peripheral glial cells. The study of contribution of different 
isoforms to this effects, as well as the analysis of the intracellular pathways 
involved, both deserve further investigation. 
 
Most of the results presented in this chapter are currently under consideration 
for publication: 
Castelnovo LF, Magnaghi V, Thomas P (n.d.)  Expression of membrane 
progesterone receptors (mPRs) in rat peripheral glial cell membranes 
and their potential role in the modulation of cell migration and protein 
expression Submitted to Steroids.  
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The different lines of research pursued during my PhD program and described in 
this thesis investigated different aspects of the GABAergic system and neuroactive 
steroids role in the patho-physiology of the peripheral nervous system. 
In particular, the first research line regarding the nerve regenerative effects of 
GABA-B ligands and the GABA-A subunits modulation in GABA-B conditional 
knockout mice suggested that GABA-B modulation in the peripheral nervous 
system may be a promising tool for the development of new pharmacological 
approaches for nerve regeneration. Moreover, these outcomes strengthened the 
hypothesis that the two GABA receptors are cross-modulated in the peripheral 
nervous system, contributing to the modulation of GABA effects in this 
compartment. For what concerns GABA-B ligands as a tool for nerve regeneration, 
future experiments will be aimed at a better comprension of the mechanisms 
underlying the observed additive effect; these studies will include both experiments 
of in situ drug delivery, to better distinguish between central and peripheral effects, 
and experiments performed using cell culture approaches, in order to better 
discriminate the contribution of neurons and Schwann cells to the observed effects. 
For what regards GABA-A subunits expression in conditional knockout mice, the 
study will proceed including sciatic nerves and Schwann cell primary cultures in 
the analysis, then evaluating also GABA-A subunits protein levels by Western blot 
analysis and immunolocalization through immunofluorescence. These experiments 
will be performed in order to better characterize the model and to understand the 
contribution of different GABA-A subtypes.  
The second research line, regarding allopregnanolone effect on PKCε expression in 
Schwann cells and DRG neurons, indicates that allopregnanolone-mediated 
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modulation of this protein kinase may indeed have a role in the control of 
neuropathic pain peripheral mechanisms. These outcomes further confirmed the 
importance of neuron-glia interaction in the modulation of neuropathic pain 
processes. Future experiments will regard the identification of the mediator 
responsible for Schwann-cell mediated allopregnanolone action on PKCε 
expression levels and localization. Moreover, the effective role of PKCε in pain 
transmission in the peripheral nervous system will be investigated with behavioural 
and/or electrophysiological approaches.  
Lastly, the analysis of mPRs presence and activity in Schwann cells deepens our 
knowledge about progestogen modulation of peripheral glial cell physiology, 
adding new players in this already complicated context. These findings will open a 
completely new line of research on the role of progestogens in the peripheral 
nervous system. The first studies will regard the identification of the molecular 
mechanism underlying the short-term effect on cell migration and the long-term 
effect on protein expression. Following studies will investifìgate the role of mPR 
activation on all the parameters that were previously shown to be modulated by 
progestogens, in order to determine the putative mPRs contribution to these effects.  
Taken together, these results shed some light on different important mechanisms 
involved in peripheral nervous system modulation. Indeed, our findings open new 
intriguing lines of research that may hopefully contribute to a better knowledge of 
mechanisms underlying inherited and acquired peripheral neuropathies, paving the 
way for the identification of more effective clinical treatments.    
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